



QuidelOrtho™



Ortho Clinical Diagnostics
2022 Sustainability Report

Transforming the power of diagnostics into a healthier future for all

Our Responsibility

As a world leader of in vitro diagnostics, QuidelOrtho develops and manufactures intelligent solutions that transform diagnostic data into answers, understanding and action for more people in more places every day to enhance clinical outcomes. We are a provider of innovative diagnostic technologies, bringing fast, accurate and reliable diagnostics when and where they are needed most — from home to hospital, lab to clinic.

As part of our environmental, social and governance (ESG) strategy we're focused on the following cornerstones:

- Monitoring waste, energy and water usage consumption
- Implementing environmentally friendly practices at our global facilities and in our product manufacturing
- Supporting equitable healthcare in our communities and fostering a culture of happy people that welcomes and promotes diversity and inclusion
- Advancing good corporate governance that aids our long-term business success
- Being accountable, fair and transparent

We believe these cornerstones contribute to fulfilling the expectations of our stakeholders and creating value for the Company and its stockholders.





Table of Contents

Introduction	Environment	Social	Governance	GRI/SASB Indices	Resources*
4 About This Report	Reducing the environmental impact of our operations and products	Doing important work in a great workplace	Becoming a public company while serving the public	38 ESG Disclosures	2021 U.K. Annual Report and Accounts
5 A Message From Our Chief Financial Officer					2022 Proxy Statement
6 About Us					2021 Annual Report on Form 10-K
8 Materiality Assessment					Code of Business Conduct
9 2021 Highlights					Corporate Governance Guidelines
					Conflict Minerals Policy Statement
					Whistleblower Policy
				41 Economic	QuidelOrtho Website
	11 Introduction	22 Introduction	30 Introduction	42 Environmental	
	12 GHG Emissions and Energy Use	23 Improving Access to Diagnostic Testing	31 Innovation	44 Social	
	14 Waste and Hazardous Materials	24 Diversity, Equity & Inclusion	33 Corporate Governance	46 SASB Index	
	17 Product Environmental Stewardship	26 Employee Recruitment, Engagement and Development	35 Product Safety and Quality		
	19 Waterless Technology and Water Use	28 Next Steps	36 Next Steps		
	20 Environmental Health and Safety Standards				
	20 Next-Generation Goals				

*As a result of the Combinations effective May 27, 2022, QuidelOrtho Corporation's [Code of Business Conduct](#), [Corporate Governance Guidelines](#), [Whistleblower Policy](#) and [Conflict Minerals Policy Statement](#) replaced Ortho's policies.



About This Report

On May 27, 2022, Ortho Clinical Diagnostics and Quidel Corporation became QuidelOrtho Corporation. This report reflects Ortho's ESG achievements in 2021, prior to becoming a wholly owned subsidiary of QuidelOrtho Corporation.

This first sustainability report covers Ortho's approach to sustainability, corporate responsibility and our global progress on environmental, social and governance (ESG) topics during fiscal year 2021. This report was developed in accordance with the core level of the Global Reporting Initiative (GRI) Sustainability Reporting Standards as well as the Sustainability Accounting Standards Board (SASB) Standards for the Healthcare — Medical Equipment & Supplies Sector.

Disclaimer: The information in this report represents Ortho during fiscal year 2021, including the goals set during such period, and is subject to change following the combination of Ortho and Quidel Corporation.

A Message From Our Chief Financial Officer

I am pleased to present the 2022 sustainability report for Ortho Clinical Diagnostics, QuidelOrtho Corporation's subsidiary as of January 4, 2022. Sustainability is not new to us — it has been part of our culture and values over the last 80 years. Ortho codified its mission with the credo, *Because Every Test Is A Life™*. This reflects the crucial role diagnostics play in global health and guided our priorities as an organization.

As an in vitro diagnostics (IVD) leader, Ortho Clinical Diagnostics impacted approximately 800,000 patients every day. Like our customers, we never forget how high the stakes are, which is why we work every day to deliver accurate test results, easy-to-use technology, and continuous collaboration to ensure our customers achieve the most important measure of success — exceptional patient care. We could not do this without the support of our board members, the dedication of our senior leaders, and the daily hard work of our colleagues around the world.

As a business, Ortho Clinical Diagnostics accomplished several important milestones in 2021, including:

- Launching the FDA EUA-approved Vitros® Anti-SARS-CoV-2 IgG Quantitative Test, our sixth novel SARS-CoV-2 assay
- Reinforcing our service leadership and earning the number one rank for the sixth consecutive year in service and support from the IMV ServiceTrak™ Awards
- Increasing our investment in product innovation, menu acceleration and commercial excellence
- Growing our core revenues at 16% to more than \$2 billion

All this was accomplished despite the challenges we faced from the ongoing COVID-19 pandemic, supply chain interruptions and our dramatic growth in recruitment.

This sustainability report covers the environmental, social and governance (“ESG”) topics most important to our stakeholders and to our business as determined by a formal materiality assessment. It showcases our 2021 accomplishments, acknowledges our challenges and sets forth goals and commitments that will be carried forward through our combination with Quidel, which occurred in May 2022.

I look forward to hearing your feedback on our sustainability strategy and this report. Please send your comments to IR@orthoclinicaldiagnostics.com.

Sincerely,

Joe Busky

Joseph Busky
Chief Financial Officer
QuidelOrtho Corporation



About Us

At QuidelOrtho, we are driven to transform diagnostic data into answers, understanding and action for more people in more places every day. Healthcare providers, public health officials, communities and individuals are able to spot trends sooner, respond quicker and chart the course ahead with accuracy and greater confidence.

For over 80 years, we've relentlessly pursued the unknown with a passion and purpose to improve health. We've offered much-needed intelligence in a world of uncertainty, and we'll continue to raise the bar, bringing clarity and insight in settings from home to hospital, lab to clinic.

We are transforming the power of diagnostics into a healthier future for all.

Ortho by the numbers in 2021*

\$2,042.8

million in net revenues

130+

countries and territories served

250+

products offered across instruments and assays

800,000

patients tested by our equipment daily

4,800

employees worldwide


~1,025

manufacturing employees

~2,300

employees in commercial sales, service and regional marketing positions including approximately 980 service teammates and over 360 laboratory specialists with advanced qualifications

Extensive and Balanced Global Footprint



~2,100

direct global teammates
focused on commercial
sales and service

Materiality Assessment

In 2021-2022, Ortho performed a materiality assessment led by an independent third party to determine the topics of greatest concern to our business and our stakeholders. Our existing material topics were benchmarked against those of three peers, and topics were requested by globally accepted reporting frameworks and major ranking and rating surveys. The resulting set of topics was then validated through external interviews representing our investor, customer and supplier stakeholders as well as industry nongovernmental organizations (NGOs) and sustainability experts. These interviews provided further insight into our current ESG state, risks and opportunities for the future, and formed the prioritized topics listed below.

More Material Topics

Less Material Topics



Environmental Impact of Products

Financial Performance

Air Quality and Emissions

GHG Emissions

Ethical Business Conduct

Public Policy and Advocacy

Employee Recruitment, Engagement and Development

Business Resilience (including pandemics)

Data Privacy and Security

Employee Health, Safety and Well-Being

Energy

Product Marketing and Labeling

Diversity, Equity & Inclusion (DE&I)

Water and Effluents

Global Health

Product Quality and Safety

Waste and Hazardous Materials

Community Engagement and Philanthropy

Social Impacts of Products

Responsible Supply Chain

Stakeholder Dialogue

Innovation and Thought Leadership

Human Rights and Labor Relations

Support for Science

Corporate Governance and Leadership

The focus areas of this sustainability report are aligned with the topics identified as “more material” in the table above, which also serves as one of the inputs to forming the QuidelOrtho ESG strategy. For more information on material topics not fully discussed in this report, we have provided links to existing sources of information to the extent available.



2021 Highlights

Business	Customer Service	Product Development	Innovation	Social	Environmental Health and Safety
<p>Completed initial public offering on February 4, 2021</p> <p>Entered into a Business Combination Agreement (the “BCA”), dated December 22, 2021, with Quidel Corporation, which was later completed on May 27, 2022, to form QuidelOrtho</p>	<p>Recognized by Stevie® Awards for Exceptional Customer Service 5 years in a row</p> <p>Won a People’s Choice Stevie Award for Worldwide Customer Service</p> <p>Ranked No. 1 in Service and Support for sixth consecutive year by customers for the 2021 IMV ServiceTrak™ Awards</p>	<p>Vitros® SARS-CoV-2 Antigen Test for accurate, mass-scale COVID-19 testing is the first widely available high-volume test to receive FDA Emergency Use Authorization</p> <p>Quantitative COVID-19 IgG Antibody Test first to receive FDA Emergency Use Authorization</p> <p>Vitros® SARS-CoV-2 Antigen Test for accurate, mass-scale COVID-19 testing is the first high-volume test to receive licensure from Health Canada</p> <p>Vitros® SARS-CoV-2 Antigen Test for high-volume testing receives FDA Emergency Use Authorization for new performance, sensitivity data</p>	<p>Named finalist by prestigious Edison Awards for COVID-19 solutions</p> <p>Recognized in 2021 with MedTech’s 2020 Outstanding Contribution to the Bio/ Med Industry Award for our COVID-19 testing solutions</p> <p>Named Clinical Diagnostic Supplier of the Year by Cardinal Health</p> <p>Finalist: <i>Fast Company’s</i> 2021 World Changing Ideas Awards for COVID-19 testing solutions</p> <p>Named as one of the Best Healthcare Brands in India at the 4th edition of The Economic Times Best Healthcare Brands 2021 Virtual Conclave</p>	<p>Named by <i>Forbes</i> as one of America’s Best Mid-Sized Employers, Top in Healthcare Equipment & Services for 2021</p> <p>Recognized as 2021 Top Employer in China by Top Employers Institute</p> <p>Ortho India recognized and certified as a Great Place to Work by the Great Place to Work Institute, India in 2021</p> <p>Honored by Blood Centers of America for Critical Contributions during the COVID-19 pandemic</p>	<p>Ortho Micro Typing Systems in Pompano Beach, FL, achieved ISO-45001 Safety Management System certification</p> <p>Ortho Raritan manufacturing and franchise headquarters in Raritan, N.J., recertified as OSHA Voluntary Protection Program Star Site</p> <p>Achieved an absolute 2% waste reduction and 15% absolute energy reduction versus our 2019 baseline as stated in our 2019-2022 Sustainability Goals</p>



Environment



Reducing the impact
of our operations
and products

Introduction

As one of the world's largest pure-play IVD companies, Ortho pioneers innovative product solutions that save lives. Our dry slide technology, along with our Vitros family of instruments — which require neither water nor drains to operate — are industry leaders in environmental efficiency and water conservation.

Conserving water aligns with the UN Sustainable Development goal to address water scarcity. Water is a critical link to socioeconomic development, energy and food production, healthy ecosystems and basic human survival. It is also a vital component in climate change adaptation strategies.

Protecting the environment aligns with Ortho's purpose of improving and saving lives through diagnostics, and we have implemented policies to conserve energy and reduce greenhouse gas (GHG) emissions, use water efficiently, and reduce waste and the use of hazardous materials.

We work to reduce the environmental impact of our products from design, sourcing and manufacturing, and encourage our suppliers and customers to recycle and reuse through takeback programs. By offering products and processes that require less energy, we help to reduce our customers' GHG emissions as well as our own.

Our focus on innovation and finding effective solutions led us to invest in pilot projects ranging from installing solar panels and a cogeneration¹ plant to partnering with suppliers to identify the best approach to medical waste recycling. We've shared the successes and failures of our sustainability pilot programs with other organizations so that they may learn from our efforts.

Our multifaceted approach will help us define, communicate and move forward with a balanced sustainability strategy that advances the company through our sustainability efforts. Annual sustainability reporting will keep us accountable.

¹Cogeneration is the simultaneous production of two or more forms of energy from a single fuel source. Cogeneration power plants often operate at 50-70% higher efficiency rates than single-generation facilities. *Scientific American*



GHG Emissions and Energy Use

Ortho recognizes the importance of reducing energy use and decarbonizing our business in line with science-based targets to reduce climate change. We are proud of our steady progress since the 1990s and have been tracking Scope 1 and 2 emissions since 2019. Tracking helps us objectively measure our strengths and weaknesses against our peers, establish new baselines and target more ambitious goals for future periods.

Current progress

Ortho’s energy consumption was down 15% in 2021 compared to 2019, even as revenue increased by 13% resulting in a 25% reduction in energy intensity. In 2021, we consumed 9% of our energy use from clean and sustainable energy sources like solar, geothermal and co-generation. Under our current three-year energy goals, all our facilities are working toward a further 4% decrease in energy use in 2022, as Ortho has decreased its absolute energy use by 24% since 2014.

Energy ratios*

	2019	2020	2021	Change from 2019 to 2021
GHG intensity in metric tons CO2e/\$-million	26.5	25.9	22.2	-16%
Energy intensity in MWh/\$-million	149.1	151.5	112.1	-25%

*Includes major manufacturing and distribution facilities located in Raritan, Rochester, Pompano Beach, Pencoed and Strasbourg.

Energy use 2014-2021 (in MWh)

	2014	2015	2016	2017	2018	2019	2020	2021
Total energy use	301,107	278,359	265,826	282,325	221,139	268,388	268,226	228,661
From sustainable sources	41,853	41,440	28,592	53,571	7,031*	46,624	55,312	16,113*
From nonsustainable sources	259,254	236,919	237,234	228,754	214,109	221,764	212,915	212,548

*New turbine engine installed in fourth quarter of 2021 to address failures in cogeneration system in 2018 and first through third quarters of 2021.

The combination of solar panels and the cogeneration unit at our Raritan, N.J., facility offsets on average of more than 9 million kWh of energy demand each year, enough to power 875 typical U.S. homes per year, and the solar panels alone offset an average of more than 2 million kWh per year, enough to power more than 200 homes.



Investments across the franchise in HVAC and building automation controls, cogeneration² reliability upgrades and building infrastructure improvements, including roofs, are the main contributors to Ortho’s success in year 2 of the 3-year goal.

In relation to GHG emissions, our flagship renewable energy project is our 7-acre solar array at our transfusion medicine manufacturing and headquarters facility in Raritan, N.J. Together with a heat recovery and electricity cogeneration power plant, Ortho is offsetting more than 9 million kWh of energy each year. These energy savings reduce the amount of energy purchased from the grid, which constitutes Scope 2 emissions.

The data collected for this sustainability report is being used to establish firm-wide carbon reduction goals based on the measurements of Raritan, N.J.; Rochester, N.Y.; Pompano Beach, FL; Pencoed, Wales; and Strasbourg, France. Our baseline has been calculated using the EPA Simplified GHG Emissions Calculator, version 7, March 2018.

GHG emissions (in metric tons CO₂e)

	2019	2020	2021	Change from 2019 to 2021
Direct	26.5	25.9	22.2	-16%
(Scope 1)	19,737	19,409	17,320	-12.2%
Energy indirect (Scope 2)	28,032	26,398	27,971	0.2%
Total (Scopes 1 & 2)	47,769	45,807	45,291	-5.2%

As stated, we are working toward a 4% reduction in energy use by the end of 2022 from a 2019 baseline, by either avoidance or by shifting to more sustainable energy sources. We are currently on track to achieve our combined energy and GHG reduction goal, which has contributed to a 5% reduction in GHG emissions for Scopes 1 and 2 from 2019 to 2021. At this pace, we are in line with the Science Based Targets initiative (SBTi) minimum recommendation of 2.5% per year,³ and we will keep pushing toward carbon neutrality.

²Cogeneration is the simultaneous production of two or more forms of energy from a single fuel source. Cogeneration power plants often operate at 50-70% higher efficiency rates than single-generation facilities. *Scientific American*

³Source of 2.5% SBTi Target: <https://www.epa.gov/climateleadership/target-setting>

“Operating a healthy business goes hand-in-hand with being green and being safe. Our vision speaks to the concerns we have for the planet as well as the health and safety of our employees.”

— Tim Goddeyne, Sr. Manager, Environmental Health and Safety, Ortho



Waste and Hazardous Materials

As stated in our Global Environmental Health and Safety Policy, we endeavor to protect the environment by reducing resource use and waste, utilizing the principles of process improvement, product stewardship and pollution prevention to strive toward improving efficiency. In this regard, we take waste and hazardous materials compliance seriously and use an environmental health and safety (EHS) management system approach to compliance, continuous improvement and environmental performance. We monitor and measure EHS data to analyze trends and identify opportunities for improvement in our processes and products. We will continue to seek more sustainable disposal methods to reduce overall waste at our facilities.

Current progress

Nearly 4 million pounds (72%) of Ortho's nearly 5.5 million pounds of waste generated each year is either recycled or reused offsite. Our goal is to identify more sustainable disposal options for the remaining waste that is either put in a landfill, incinerated or disposed to sewer. Our 2019-2022 goal is to achieve a 5% shift of waste from landfills to more sustainable disposal methods or to reduce the amount of waste we generate by this amount. The COVID-19 pandemic disruptions of 2020 had an impact on our operations and waste management. As we experienced an increased demand for our products, leading to increased manufacturing, our recycling partners struggled to meet our pickup frequencies and disposal preferences. However, in 2021 we were able to correct these waste-hauling supply chain issues resulting in our

nonhazardous waste recycling to improve by 19% from the previous year (6% improvement from base year 2019). Additionally, total waste diverted from landfill decreased by 1% from the base year of 2019.

Between 2019 and 2021, we achieved a 2% absolute reduction (8% reduction when indexed to production) in waste generation. Here are a few examples of our manufacturing colleagues' accomplishments supporting our sustainability goals:

- By upgrading to more sophisticated visual inspection systems that check for certain quality attributes of our products, we can rework most items that would otherwise be rejected. Whether vials, bottles or slide cartridges, we can reintroduce them back into the assembly process, eliminating nearly all finished scrap off the line.
- Process excellence and manufacturing yield play a significant role in managing the amount of nonfinished product output associated with quality sampling and over-production to cover labeling and packaging rejects. A waste avoidance project in 2019 reduced 100,000 vials from unnecessarily being filled and scrapped each year.
- Shown right are images of polystyrene plastic collection processes. Combined, this granulated plastic along with uncontaminated slides, slide cartridges and trimmings from operations and customer takeback accounts for 1.5 million pounds of plastic that are sent offsite for recycling into many commercial products made of plastic recycled material.

Nearly 4 million pounds (72%) of Ortho's nearly 5.5 million pounds of waste generated each year is either recycled or reused offsite.



Waste disposal

We continue to explore more sustainable disposal methods for hazardous materials within a circular economy. Our facilities face higher costs for hazardous waste disposal in addition to increased public reporting requirements. While examining waste profiles, we discovered that separating hazardous waste by type, rather than shipping commingled waste for disposal, presented an opportunity for offsite reuse. Instead of disposing of mixed acetone solvent, for example, thousands of gallons are now returned to the chemical supplier at the Eastman Business Park where our Rochester, N.Y., facility operates. Since the acetone waste stream accounts for 61% of our total hazardous waste, the ability to reuse this waste stream significantly reduces our environmental impact. And since it stays on the same site, we avoid shipping hazardous waste long distances to another facility and back.

When Ortho is on the receiving end of product or packaging waste, we must dispose of it responsibly. Ortho has found ways to give a wide variety of plastic and packaging materials a second life through recycling. Shown at right is a summary of our quantified waste disposal methods.

Ortho has committed to several energy efficiency, waste management and consumption initiatives. These include recycling one million pounds of polystyrene per year from slide manufacturing, donating thousands of pounds of sheet paper and plastic liners to school arts-and-crafts programs and achieving zero waste-to-landfill status at our Pencoed site in the U.K.



Painting from Pompano Beach High School on donated paper board from Ortho collecting and reusing slip-sheets

Hazardous waste by disposal method (pounds)	2019	2020	2021
Recycled/reused (HSM)	321,680	301,200	393,318
Energy recovery	450	909	450
Incinerated	159,652	170,005	173,147
Treated and landfilled	—	10	—
Bio/chemical treatment	69,923	65,934	78,913
Total hazardous waste	551,458	538,058	645,828
Medical waste (pounds)			
Recycled	6,458	—	—
Incinerated	176,722	198,473	219,290
Other - Treated, destroyed and disposed	139,928	129,619	120,064
Total medical waste	323,108	328,092	339,354
Nonhazardous waste by disposal method (pounds)			
Recycled/reused	2,827,428	2,508,817	2,988,400
Energy recovery	784,647	547,585	545,687
Incinerated	39,077	19,350	40,198
Landfilled	1,024,571	914,759	888,880
Bio/chemical treatment	—	—	21
Total nonhazardous waste	4,675,723	3,990,511	4,463,186



Packaging

Ortho's approach to packaging has always been to keep it minimal. The tertiary corrugated boxes used to ship our products contain a minimum of 70% post-consumer recycled content. The paper stock in our primary packaging comes from certified Forest Stewardship Council (FSC) sources, and we reuse our wooden pallets. We strive to maximize the recyclability of the packaging we create by eliminating colorful designs, laminated materials and glossy finishes, and using the smallest possible amount of ink.

In 2018, we designed an ID-Micro Typing System™ (ID-MTS™) Gel Test card packaging solution (shown below). The newly designed molded pulp insert is composed of 100% post-consumer recycled materials and protects the product by storing it in the correct upright position at the right temperature. The new packaging not only eliminated plastic from ID-MTS Gel Test cards packaging but also reduced the total amount of material in the shipping box. This sustainable, lower-cost solution can now be recycled or composted, reducing our customers' waste.

We share our customers' concerns about plastic waste and are working to reduce plastic packaging and identify "greener" alternatives. We also seek sustainable approaches to using and recovering plastics in our supply chain and operations. We have taken back approximately 25,000 pounds of Vitros® Empty Cartridges annually for recycling from customers who have no local options to do it themselves.




So, what do Ortho MTS Gel Cards and eggs have in common? Packaging! The molded insert is composed of 100% post-consumer recycled materials and can be recycled or composted, and resulted in the removal and final disposal of 37,200 pounds of plastic air-filled dunnage. Based on domestic and international units shipped (2018-2021)

Product Environmental Stewardship

At Ortho, we have a long history of innovative, efficient product lifecycle design and ensure that our products excel at every stage. Our diagnostic equipment requires a smaller blood sample to initiate twice as many test processes as competitors, delivers various test results that can run simultaneously from the same blood sample, generates less waste and provides a highly accurate result almost twice as fast. Our analyzers require no water, avoiding the use of millions of gallons per year, and can be run anywhere, with a 98% uptime

rate (the percentage of time the machine is available for testing minus warm-up, calibration and maintenance downtime). During use, we provide world-class customer support and, at end of life, we offer refurbishment and takeback programs. We also strive to eliminate potentially hazardous substances from our products.



XT MicroSlide Technology

“Globally, but especially in Eastern Asia and Europe, customers are more concerned about the plastic waste being generated, and it’s part of their tender criteria now, along with some specific chemicals that they no longer want to see as part of the equipment or the reagents.”

— JP Antoni, Environmental Product Compliance Manager, Ortho


“Innovation is not just about giving birth to an idea.

It’s the translation of an idea to a practical reality for the entire ecosystem.”

— Sergey Gershtein, Head of Advanced Research and Development, Ortho

We are fully committed to following sound environmental management practices, including but not limited to compliance with the EU RoHS Directive (Directive 2011/65/EU and amendment 2015/863) and other comparable regulations in the markets we operate in. Such compliance has resulted in us restricting ten hazardous substances in the manufacturing of our products that may pose risks to human health and the environment. We maintain an active multi-year compliance program, in partnership with our suppliers, to ensure that the systems currently being manufactured, and any equipment changes, utilize only RoHS-compliant components.

Our new XT MicroSlide technology, pictured above, also provides multiple sustainability advantages. It enables two clinical chemistry tests to be performed simultaneously, as much as doubling system throughput for paired requested tests. The technology reduces the amount of reagent handling by the system operator and, by reducing the required blood sample volume, the TBIL-ALKP XT MicroSlide also benefits patients. This slide even contains less plastic waste than other slide technologies of our competitors.



Another recent change that made a big impact was eliminating printed Instructions for Use (IFU) and product reference manuals. By posting all manuals online, we avoid the creation of thousands of booklets that are eventually discarded. For example, in looking at Ortho reagents alone put on the market in the United States between 2019-2021, we avoided the use of 57.6 million pages of paper (2.3 million pounds). This sustainability initiative equates to 27,500 trees saved or 428 acres of forest conserved.


We also take care that our products are safe for customer use and are responsibly produced. Ortho maintains an Environmental Product Legislative Compliance (EPLC) committee that evaluates the safety of various raw materials and components we receive from suppliers to ensure such raw materials and components meet our strict customer safety, environmental and product compliance requirements. If any components do not meet our standards, we work closely with our suppliers or our Research and Development Team to find replacements without compromising performance.

In 2021, following our IPO, we expanded our conflicts minerals program in light of the disclosure obligations required by the U.S. Securities and Exchange Commission

applicable to public companies whose products contain conflict minerals, such as tin, tantalum, tungsten and gold, which originate from the Democratic Republic of Congo and/or adjoining countries.

We estimate the average lifetime of our analyzers to be a little over a decade at the initial customer. Embedded in our strategy of developing new integrated analyzers and bringing them to market is the parallel refurbishment of used analyzers at one of our multiple refurbishment centers. These instruments are then resold to more cost-sensitive customers, expanding access to healthcare in underserved areas, particularly those in emerging markets. There is no performance difference between a new product and one that has been refurbished, so there are many analyzers more than 25 years old that continue to provide diagnostic insights to providers for the treatment of patients around the world. In addition to this expanded access to healthcare, the more we keep reviving our analyzers, the less waste we are responsible for discarding.

When an analyzer has exceeded its effective life, we harvest it for parts to keep other analyzers running before finally adding it to our recyclable waste disposal stream.



Between 2019 -2021 we
avoided the use of
57.6
million
pages of paper
(2.3 million pounds)

This sustainability initiative equates to
27,500 trees
or 428 acres of forest conserved

Waterless Technology and Water Use

By 2030, Morgan Stanley predicts that the global demand for fresh water will be 40% higher than the available supply. We have been a pioneer of important technological advances in clinical diagnostics, including our unique dry slide technology which combines the spreading, masking, scavenger and reagent layers into one postage-stamp-sized slide that provides clinicians with high-quality results quickly, efficiently, and economically. Our slides are very stable and have long shelf life. Our dry slide chemistry is well positioned for rising environmental concerns given its eco-friendly profile with no water usage and significantly reduced clinical waste and biohazard.


In addition, Ortho's Vitros® Analyzers are waterless and revolutionary because they don't consume freshwater to operate, eliminating the need for a dedicated wastewater connection. This not only helps our

customers substantially reduce their water usage by millions of gallons per year but also helps customers in remote locations including regions where water is scarce and infrastructure can be unreliable.

We also strive to use water responsibly and continuously look for ways to reduce water consumption, especially at our locations in areas of water scarcity. We identify activities to eliminate wastewater from our operations, in addition to offering customers our water-saving product technologies. From 2014 through 2021, Ortho has reduced its water consumption by more than 20 million gallons or 16% — while increasing our manufacturing volume by an estimated 29%. Traditional wet chemistry systems used in clinical laboratories can consume thousands of gallons of water and produce wastewater with particulate matter.



On average, 160,000 liters of water per year are saved with one Vitros System.



Environmental Health and Safety Standards

In our facilities, we strive to meet or exceed the highest employee health and safety, and environmental management systems, standards.

- All our manufacturing sites are ISO 14001-certified for environmental management.
- Our Pompano Beach, Florida, facility is ISO 45001-certified for occupational health and safety.
- Our Raritan, New Jersey, and Rochester, New York, sites are Occupational Safety and Health Administration (OSHA) Voluntary Protection Program (VPP) Star sites.



The VPP Star site designation is the highest designation a facility can receive — it recognizes employers and workers in private industry and federal agencies that implemented effective safety and health management systems and maintained injury and illness rates below Bureau of Labor Statistics national averages. We are proud to have two qualifying sites.

Next-Generation Goals

Historically, Ortho set new ESG goals every 3 years. We expect that QuidelOrtho will also establish ESG goals prospectively, which will entail the following 4 focus areas.

1. Reducing our environmental impact by:

- Developing and executing a GHG emissions disclosure strategy.
- Setting GHG near-future and long-term reduction targets based on science-based targets.
- Establishing our waste minimization strategy, which may entail shifting a large percentage of nonhazardous waste to sustainable disposal methods.

2. Enhancing supply chain sustainability by:

- Setting a packaging waste reduction and content target.
- Developing new supplier sustainability practices.

3. Improving our product sustainably by:

- Shifting our commercial and manufacturing operations, our products, our shipping practices and our facilities to adopt more environmentally friendly practices.
- Investing in renewable energy.

4. Enriching employee workplace and community relations by:

- Implementing DE&I initiatives.
- Reducing recordable employee injuries and lost-time accidents.

Social



Doing important
work in a great
workplace

Introduction

Ortho is a global leader of IVD, dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions.

The work we do has meaning and value, and the stakes are high. Physicians and other medical professionals rely on our tests to indicate a serious illness or confirm its absence, and our blood-typing and screening tests ensure that donated blood is safe to use. We know that our work is important, and our shared sense of purpose and responsibility unites us, as expressed in our brand promise — Because Every Test Is A Life™.

Every day, more than a million diagnostic tests are performed with Ortho equipment, affecting about 800,000 patients worldwide. We support our instrument and assay offerings with our Customer Excellence ethos to bring best-in-class technical, field and remote service to customers in more than 130 countries and territories around the globe. In an era where roughly 70%⁴ of all medical decisions are based on laboratory test results, we deliver holistic solutions that deliver fast and accurate diagnostic insights.

- Every two seconds,⁵ someone in the U.S. needs donated blood or platelets.
- More than 118 million⁶ units of blood are donated globally each year, and it still isn't enough to treat all the people who need transfusions.

Our employees responded to the continued challenges of the pandemic with resilience and determination, making a successful transition from our offices to a virtual work environment. We provide Global Employee Assistance programs to all employees, which includes free, confidential, mental health support services available 24/7 to address emotional strain and encouraged employees to take days off to volunteer.

Despite these obstacles, we completed our initial public offering in February 2021 and continued to execute by launching new products and winning awards (see 2021 Highlights page 9 and Innovation page 9). We delivered strong performance in 2021, due in part to the demand for our innovative COVID-19 testing solutions.

Our rapid growth led to more new hires in 2021 than any year in our history, and we launched a new global Diversity, Equity & Inclusion (DE&I) initiative to ensure that we continue to provide a world-class workplace where diverse perspectives are valued and all our employees around the world can grow and thrive. We also stepped up our recruitment and development programs, reaching out in new and novel ways to potential employees and increasing opportunities for our current employees.

⁴Centers for Disease Control and Prevention. Strengthening Clinical Laboratories. Accessed April 19, 2022. <https://www.cdc.gov/csels/dls/strengthening-clinical-labs.html>

⁵American Red Cross. Facts About Blood Supply In The U.S. Accessed April 19, 2022. <https://www.redcrossblood.org/donate-blood/how-to-donate/how-blood-donations-help/blood-needs-blood-supply.html#:~:text=The%20Red%20Cross%20provides%20about%2040%25%20of%20our,6.8%20million%20people%20in%20the%20U.S.%20donate%20blood>

⁶World Health Organization. Blood Transfusion. Accessed April 19, 2022. <https://www.who.int/news-room/facts-in-pictures/detail/blood-transfusion>



Improving Access to Diagnostic Testing

Access to fast, accurate testing leads to more effective diagnoses and early treatment, which can lead to better patient outcomes and help to address health inequity. Lack of or restricted access to testing and treatment can have dire consequences. According to The World Health Organization (WHO), when patients cannot receive a needed transfusion, a poor outcome and even death can result.

The U.S. Centers for Disease Control and Prevention (“CDC”) reports that patients in rural areas often face barriers to healthcare and laboratory services that limit their ability to receive care. In addition, diagnostic errors, which cause death or injury to 40,000 to 80,000 people each year in the U.S. alone,⁷ are most common in primary care solo practice due to heavy workload and inability to consult easily with colleagues — conditions that many remote or rural healthcare workers face every day.

Ortho’s VIRTOS® Systems may improve access to fast, efficient and accurate diagnostic testing in certain communities that use the system. For example, it has a 98% uptime (less than 2% idle time), which helps sparsely staffed labs complete more tests during each shift. Additionally, with a 96.5% first-pass yield, our customers get the right results the first time, avoiding stressful redraws and repeat tests empowering clinicians to make confident treatment decisions. Among our goals is to increase the availability and broaden access to our diagnostic

equipment. Our refurbished analyzers are a good example of working toward these goals, as they are resold to more cost-sensitive customers, expanding access to healthcare in underserved areas, particularly those in emerging markets.

In the early days of the COVID-19 pandemic, Ortho employees visited disaster zones to set up equipment, even in places where the company didn’t have relationships with any nearby hospitals. Because we take back and refurbish our analyzers, these encore products are perfect for stocking a clinic or hospital with a tight budget and providing diagnostic testing access to currently underserved communities facing health inequality.

The unique waterless technology of our dry slide products may also improve access to diagnostic testing by enabling Ortho products to be used at facilities in communities with scarce or unreliable water supply and drainage capabilities. Our products can function in a variety of settings, including remote locations, areas with water scarcity and regions struck by severe weather disasters. Ortho analyzers also conserve thousands of gallons of water a year and produce less waste than competitor equipment.

Our waterless analyzers are also simpler to use and much more reliable in locations without easy access to repair services, like many of the small, rural hospitals and U.S. Indian Health Services locations Ortho employees have equipped.

“Affordability and accessibility to healthcare for a major part of humanity is our big goal. Today, we touch approximately 300 million patients a year using our technologies. Our aspiration is that by 2030, we will touch a billion people. We have to fundamentally change the way we do things, meaning the technology has to be democratized so that a large portion of the global population has access to it.”

— Michael Iskra, Executive Vice President and Chief Commercial Officer, Ortho

⁷Rodziejewicz TL, Houseman B, Hipskind JE. Medical Error Reduction and Prevention. [Updated 2022 Jan 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK499956/>

Diversity, Equity & Inclusion (DE&I)

Ortho does business in more than 130 countries and, as of January 2, 2022, 51% of our employees were located outside of the U.S., primarily in Europe and Asia. Our strong, multinational organization is comprised of unique ethnicities, cultures, heritages, experiences and abilities, which enables diverse perspectives to drive more creative and innovative ideas and results. We recruit and develop employees from diverse backgrounds and cultures to fulfill our mission and deliver upon our commitment to customer excellence around the globe, ultimately ensuring their patients receive exceptional care no matter where they are.

Early in fiscal year 2021, Ortho established a DE&I Council with a mission to foster a collaborative and innovative organization, ensure all teammates lead with an inclusive mindset, and feel confident that their voices are being heard. Building on the foundation of our comprehensive business and employment-related policies and programs, including but not limited to our Code of Business Conduct and Ethics (the “Code of Conduct”), the DE&I Council is a cross-functional, volunteer-led group with members throughout the world.

In 2021, the DE&I Council implemented various programs to build knowledge, increase awareness and promote a culture of belonging. Through internal and external communication campaigns consisting of internal articles, employee and manager newsletters and social media posts, the DE&I Council announced DE&I events (like a

two-part series on Unconscious Bias), celebrated Martin Luther King Jr. Day, Black History Month, International Women’s Day, Diwali and Veterans’ Day and observed National Hispanic Heritage Month, Juneteenth and Global Diversity Awareness Month. The DE&I Council is also engaging and supporting the six Employee Resource Groups (ERGs) that were formed by enthusiastic employees across our company as follows:

- African American Leadership Council (AALC)
- Lesbian, Gay, Bisexual, Transgender and Queer (LGBTQ) Alliance
- Hispanic Organization for Leadership and Achievement (HOLA)
- Millennials
- Ortho Women’s Network (OWN)
- Veterans Leadership Council (VLC)

As the “baby boomer” generation is nearing retirement, many industries find that they need a way to retain the valuable knowledge of this employee population who has extensive historical knowledge and experience before they retire. To remedy this potential knowledge gap, our ERGs create a venue for employees of all ages to connect and share their experiences. We’ve made good progress in our first year and plan to build on that momentum to evolve our initiatives.

“The mission of the DE&I Council is to foster a culture that supports diversity and an environment of mutual respect, equity and collaboration that helps drive our business.”

— Gina Dunsmuir, Vice President,
Associate General Counsel, Ortho

Integral to our talent management processes is Ortho's Leadership Attributes model, which defines critical leadership behaviors for all employees. These attributes guide the way we work together and are reflected in our hiring and performance management practices. We expanded our focus on behaviors and implemented company-wide DE&I training in 2021, including virtual, interactive sessions about unconscious bias which were reinforced with toolkits, videos and its prevalence during talent management decisions. Several virtual sessions were also hosted for managers on the importance of leading with inclusivity. Voluntary DE&I training was a popular element of our recently launched comprehensive LinkedIn Learning offering, which enabled employees to create their own learning plan from 16,000 available courses. Our employees accessed over 50,000 course sessions in 2021, representing more than ten courses per employee.

We embrace diversity not only at the board-of-directors level but throughout our global employee population. For example, as a U.S. government contractor, we maintain Affirmative Action Plans to ensure that the employee population at each U.S. location reflects the diversity of the locally available workforce. We set annual gender diversity goals for different types of employees (for example, engineers, managers and executives). We also have partnerships with community and national organizations to develop a talent pipeline of

women, minorities, veterans and people with disabilities, among other groups. Organizations we work with include:

- Historically Black Colleges and Universities
- The National Black MBA Association
- Society of Asian Scientists
- National Society of Black Engineers
- Healthcare Businesswomen's Association
- Women in Manufacturing
- Veterans Outreach Center
- Refugee Center of Binghamton (NY)

We shared our Career Fair at our Raritan headquarters with over 80 local organizations including the YWCA, Rutgers and TCNJ Women/Minority organizations, Dress for Success, Disabled American Veterans, County One Stop Career Centers, NJ Institute for Social Justice and African American Chamber of Commerce.

Our commitment to DE&I also extends throughout our supply chain, and we are committed to developing mutually beneficial relationships with suppliers that also embrace these values. We believe that we have a responsibility to engage with businesses whose employees reflect the diversity of their communities, and we look to partner with and expand opportunities for diverse suppliers by incorporating them into everyday category reviews and product or service bids. To see our EEO-1 reporting data, please see disclosure 102-8 in the GRI Index on page 38.

Gender diversity by region 2021 Count of Worker WWID

Region	Gender	Regular full time	Part time	Total
ASPAC		319		319
	Female	72		72
	Male	244		244
	No info provided	3		3
Canada		53		53
	Female	26		26
	Male	26		26
	No info provided	1		1
Greater China		397	1	398
	Female	164		164
	Male	228	1	229
	No info provided	5		5
EMEA		1,052	47	1,099
	Female	423	45	468
	Male	604	1	605
	No info provided	25	1	26
Japan		207	2	209
	Female	41	2	43
	Male	165		165
	No info provided	1		1
LATAM		341	3	344
	Female	146	2	148
	Male	171		171
	No info provided	24	1	25
U.S.		2,327	19	2,346
	Female	905	16	921
	Male	1,384	3	1,397
	No info provided	28		28
Grand total		4,696	72	4,768

Employee Recruitment, Engagement and Development

Recruitment

We believe our success depends on our ability to attract, retain, develop and motivate diverse highly skilled personnel. The substantial growth of our business in 2021 required a dramatic increase in our recruitment efforts. We leveraged our strategic pillars of growth, innovation and Customer Excellence coupled with our soaring brand recognition, partly driven by an intense interest in our COVID-19 testing capabilities, to bypass employment agencies in favor of a direct outreach hiring campaign.

We connected with diversity councils and forums in the U.S. to post positions, advertised on billboards and the radio, and offered bonuses for employee referrals of qualified applicants. Our campaign was successful, and we hired 700 new employees in 2021, the most ever in a single year. We also promoted 450 colleagues into senior positions and piloted 120 stretch assignments to challenge employees in new career roles.

To retain our top talent, we strengthened our benefits package, urged employees to take care of their health and well-being, and encouraged employees to take time off to volunteer.

Engagement


All managers at Ortho are accountable for driving employee engagement and developing talent. Our “One Ortho” ethos encompasses working together across the organization and around the world to deliver the best for our external and internal customers. This is about how the organization

collaborates, across regions and functions, to gather inclusive insights and partnerships and to avoid “group think.” In Q4 2021, 3,600 employees responded to a check-in survey evaluating their mindset during the continued COVID-19 pandemic and how Ortho could help. Most employees (85%) generally adapted to the global environment and were feeling good, well and even great. However, in a high-growth environment, they also requested improvements in prioritization, a focus on overall well-being and a greater career development focus. In response, Ortho is enhancing the Workplace Flex model and expanding the number of opportunities in which we celebrate successes to better show employees how their many accomplishments are appreciated and impactful across the organization.

Throughout 2021, we also supported an informal volunteering program to provide time off and encourage our colleagues to pursue their passions with organizations of their choice.

We offer up to 16 hours of paid time off each year through Volunteer Leave. Our U.S. employees are encouraged to volunteer for eligible projects and organizations in their communities. A companion effort, our annual One Ortho, One World Day, provides a venue for volunteering and encourages people to take time off to recharge, perform an environmental or social volunteer activity and celebrate their successes. Many employees donated their time to nonprofit organizations such as Habitat for Humanity or donated much-needed blood to local hospitals, and many departments and employees around the world organized walk/run events for charities.

Employee voluntary turnover rates 2019-2021





Development

In 2021, we focused on promoting employee growth, particularly through experiential development. As a public company, we are taking a long-term perspective on building a robust talent pipeline through which every employee plays a role in growing Ortho's leadership position and encouraging curiosity, self-awareness and a commitment to customer excellence.

Our intentionally flat organizational structure promotes agile decision making, high accountability and elevated responsibility, leading to an engaged culture. In contrast to the hierarchical structure typical of many large companies, our wide, shallow organizational chart provides greater autonomy for individuals, leading to more personal decision making and an entrepreneurial mindset. With fewer levels of approval, employees at any level can step into a more challenging role, demonstrate leadership and make an impact.

Our focus on customer excellence also contributes to high employee engagement, and our mission, philosophy and a shared sense of responsibility Because Every Test Is A Life™ provides meaning and value to all our employees.

Workplace recognition

For the second time, *Forbes* recognized Ortho as one of America's Best Mid-Sized Employers. We ranked No. 1 in the Healthcare Equipment & Services category and No. 20 overall out of 500 companies, based on a survey of 50,000 Americans working for businesses with at least 1,000 employees.

In 2021, Ortho was recognized as a Great Place to Work in India by the Great Place to Work® India and a Top Employer in China by the Top Employers Institute. These awards in China and India are notable given the competitiveness of the labor markets in these high-growth markets, which account for 13% and 4% of our core revenues, respectively.

Ortho's CEO was also featured in a *China Harvard Business Review* article documenting employees' "incredible resilience, agility and unyielding commitment and servant's heart during the pandemic — including help with pop-up hospital build-outs across China and especially in Wuhan." The article also recognized the "speed at which Ortho developed leading assays to help combat COVID-19."

"We are proud to have once again been named by Forbes as one of America's Best Mid-Sized Employers. This year's recognition is particularly special as it provides testament to our team's resiliency and commitment to our customers and their patients during the COVID-19 pandemic. We came together and were able to leverage our amazing spirit of collaboration to be part of the COVID-19 solution across all teams and regions."

— Michael Iskra, Executive Vice President and Chief Commercial Officer, Ortho

Next Steps

IMPROVING ACCESS TO DIAGNOSTIC TESTING:

- Continuously improve our equipment and services so we can help more patients benefit from quick, reliable diagnostic testing.
- We currently offer 50 unique diagnostic tests using waterless technology, out of our 200 possible diagnostic tests that a doctor can order for a patient. We aim to offer all 200 tests over the next several years using waterless technology.

DE&I:

- Continue our efforts to attract and retain top talent including providing strong, market-aligned benefit programs and employee-focused initiatives.
- Continue to report gender and minority statistics for our government contractor required Affirmative Action Plan summary and set new goals at the beginning of each calendar year based on market data.
- Continue to promote greater participation in the ERGs, support new DE&I initiatives of QuidelOrtho and seek partnerships with other global leaders to increase diversity.

EMPLOYEE RECRUITMENT, ENGAGEMENT AND DEVELOPMENT:

- Now that the Combination with Quidel has been consummated, we look forward to co-leveraging strengths in partnership with Quidel and new growth opportunities as a combined company.



Governance



Becoming a public
company while
serving the public

Introduction

Ortho draws on more than 80 years of knowledge and innovation to develop new products and processes, so we were well-positioned to create game-changing solutions for the COVID-19 pandemic and pave the way for more testing as the virus mutated.

Our committed culture and focus on high-quality targets to ensure that our products are safe, reliable and ready to help our customers provide accurate diagnoses.

Because Every Test Is A Life™, It's More Than Diagnostics

During the COVID-19 pandemic, our employees came together to ensure these new tests arrived at our customers' locations and to provide installation and technical support to help overwhelmed healthcare workers.

We are supported by a robust corporate governance structure and exceptional leadership, as well as strong business continuity and risk assessment processes. All of these factors helped to guide our growing workforce through the transition as we became a public company in 2021.

Throughout the year, we weathered unpredictable material and labor shortages but succeeded in delivering to our customers. We reinforced our reputation for customer service by supplementing with volunteer pop-up COVID-19 testing centers when needed.



Innovation

Innovation is a core focus at Ortho, but innovation is more than just having a good idea. To ensure the success of our business, we must consider all three stages of innovation: *Inspiration, Invention and Industrialization*.

Inspiration is the moment when a solution to a problem suddenly comes to mind. Someone has an exciting idea that might solve a big problem and improve or even save patients' lives.

The next stage involves rigorous testing to see how the approach performs under a wide range of conditions and situations. When we're certain the solution has proved valid, the idea has become an *invention*.

The third stage is to determine if the solution can be mass-produced for distribution to current customers and new markets. The discussion starts with our R&D team and continues with regulators, commercial teams, supply teams, manufacturers and others. If it turns out that the invention can be timely and economically produced, we're ready to begin *industrialization* and bring a new product to market.

Trailblazing COVID-19 solutions⁸

We were an early leader in testing for the COVID-19 virus and antibodies. In March 2020, when the COVID-19 pandemic was sweeping across the U.S., Ortho scientists developed a COVID-19 diagnostic innovation that was effective, accurate and could be reproduced quickly.

1. In just 19 days, Ortho conceived, produced and launched the **first-ever high-volume COVID-19 Total Antibody test** with an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). It detects all COVID-19-related antibodies

that appear in the early, acute stage of infection, and can help determine the onset of a patient's immune response to the virus.

- Two weeks later, we received an EUA from the FDA for our **Vitros® COVID-19 IgG Antibody Test**, which detects a protein that the body typically produces in the later stages of the infection. These tests show if a patient has been exposed to and developed antibodies to SARS-CoV-2. Both tests have 100% specificity, meaning they accurately identify patients without the disease 100% of the time.
- Our third COVID-19 solution, the **Vitros SARS-CoV-2 Antigen Test**, helps confirm whether a patient has an active infection by detecting viral proteins in swab samples.

We continued to lead the way with the first high-volume antigen test to receive an EUA from the U.S. FDA. Ortho ramped up production by November 2020 to facilitate mass-scale testing and deliver same-day results to help hospitals and reference labs address testing backlogs, supply shortages and delayed results.

In 2021, we launched and received EUA in the U.S. for our Quantitative COVID-19 IgG spike antibody assay. There are multiple studies underway to advance our understanding of COVID immunity, including immunity from infection and immunity from vaccination, as well as immunity to different variants. Notably, we are collaborating with academics and government agencies to develop studies to enable broader clinical utility of our Quantitative COVID-19 IgG Assay, including a large CDC-funded study in partnership with Quest Diagnostics to further the understanding of an individual's immune response to infection and vaccination.

“When the pandemic began to surge in 2020, we knew we could make an immediate difference and came together to launch and market reliable tests to help clinicians get the results they needed as fast as possible, and labs better serve their communities. Our team demonstrated an unyielding commitment to our customers and their patients during this time. We are incredibly proud to be part of the COVID-19 solution.”

— Bryan Hanson, Head of Clinical Labs Strategic Business, Ortho

⁸Ortho Clinical Diagnostics. Ortho Named Finalist By Prestigious Edison Awards for COVID-19 Solutions. Accessed April 19, 2022. <https://go.orthoclinicaldiagnostics.com/global/en/resources/press-releases/ortho-named-finalist-by-prestigious-edison-awards-for-covid-19-solutions>

Ortho Clinical Diagnostics. Ortho Clinical Diagnostics Named Finalist in Fast Company's 2021 World Changing Ideas Awards. Accessed April 19, 2022. <https://go.orthoclinicaldiagnostics.com/global/en/resources/press-releases/ortho-clinical-diagnostics-named-finalist-in-fast-companys-2021->

Fewer materials, more speed

For more than 20 years, our waterless analyzers have been saving our customers and our planet millions of gallons of water (25,000 liters for every 1 million blood donations). Now we're finding ways to reduce our energy and material use. For example, traditionally, the plastic consumable used during blood screening is half the size of a U.S. letter envelope. Our waterless dry slide technology replaces it with one the size of a U.S. postage stamp. It takes a fraction of the amount of blood previously needed and provides results in 10 minutes, rather than the hour other competitor tests require.

Automation

Even before the COVID-19 pandemic, we knew that automated analyzers would be in demand. With recent medical worker shortages, automation has only become more vital. The 98% uptime rates of our analyzers enable medical workers to efficiently run tests and our award-winning customer service continues to help overburdened labs worldwide.

Providing help and delivering hope

The COVID-19 pandemic didn't deter Ortho from delivering exceptional service when our customers were overwhelmed and exhausted. We designed

our COVID-19 testing solutions to work on the Vitros® Systems already owned by thousands of customers around the world. With no need for additional training, they could quickly begin using the new tests.

Recognitions

In 2021, Ortho received several accolades for our pioneering work in COVID-19 diagnostics:



- *Fast Company* named Ortho as one of 400 finalists in their **2021 World Changing Ideas Awards, Pandemic Response Category**. The awards honor social good, highlighting products and concepts that make the world better.




- Our rapid-response COVID-19 testing solutions were chosen from among 7,000 other products to win a **Silver 2021 Edison Award**. Established in 1987, Edison Awards honor excellence in new product and service development and innovation.



- Also in 2021, Ortho won **MedTech's 2020 Outstanding Contribution to the Bio/Med Industry Award**.

Since our waterless analyzers are uniquely suited for any setting, our team members were able to install analyzers in two "pop-up" hospitals in Wuhan, China, in the early days of the pandemic. Other team members played key roles in setting up remote testing locations at field hospitals around the U.S.



Corporate Governance

Amid Ortho's record-breaking sales and workforce growth in 2021, we continued our transition from a private to a public company.

We carefully examined our structure and culture to identify needed changes. One priority was to enhance the diversity of our board and ensure a majority of independent directors. We also established qualification standards for our Nominating

and Corporate Governance Committee to consider for director candidates, including, but not limited to, experience, gender, age, geographic background and ethnicity. Nine of our 11 directors qualified as independent under Nasdaq listing rules. Two directors identified as female, one as Asian and one as Hispanic or Latinx.

In 2021, our board had an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee

and an Executive Committee. Except for our Executive Committee, each of these committees operated pursuant to a written charter setting out the functions and responsibilities of the committee. In September 2021, Ortho completed an underwritten secondary offering of shares held by our then-principal stockholder, resulting in the company no longer being a "controlled company" pursuant to the Nasdaq Listing Rules. At that time, we transitioned to more robust corporate governance practices resulting in our Audit and Compensation Committees being fully independent.

ESG governance responsibilities were divided among several upper-level executives, and metrics were tracked on an internal dashboard.

Becoming a public company required us to establish or update essential policies to guide our employees. We adopted a new Code of Business Conduct and Ethics, an Anti-Corruption Policy, a Data Privacy Policy, a Global Environmental Health and Safety Policy and a Supplier Code of Conduct. We also launched training on insider trading based on the Company's Insider Trading & Compliance Policy. We continued to encourage the use of our hotline for concerns and complaints, and the use of our Whistleblower Policy for reporting ethics violations. In the past two years, the number of complaints we've received through the hotline has decreased, possibly because more employees have been working from home.

Upon completion of the Combinations, QuidelOrtho adopted corporate governance documents and charters, which are located on our website at [quidel.com/investor](https://www.quidel.com/investor).



Cybersecurity and data privacy

Although cybersecurity risks are a fast-moving target, our Information Security team has been focused on monitoring and addressing cybersecurity risks. We recently upgraded one of our main transfusion products to its latest operating system and added more advanced security, detection and response capabilities to the system to enhance security for that possible entry point into our customers' networks.

After an intense review by U.S. federal cybersecurity experts, we obtained an Authorization to Operate for our waterless Vitros Systems. This security clearance designation is required to operate within any U.S. military hospital or blood bank. We not only continuously monitor security controls within our operations and throughout our enterprise and offices, but also are assessing additional risks and looking at ways to better protect intellectual property and IT assets.

“We always say that we can have security without privacy, but we can’t have privacy without security. So that partnership between privacy and security has been huge for us in 2021 as more regulations come into play.”

— Patty Ryan, Chief Information Security Officer, Ortho

Further, as a global organization, Ortho is obligated to comply with various privacy legislations including the United Kingdom’s GDPR, European Union’s GDPR, Brazil’s LGPD, China’s PIPL as well as the various state-specific regulations such as California CCPA and CPRA. Ortho has put in place global and regional privacy staff to understand these specific regulations and their impact on our business. By leveraging privacy automation tools and cross-functional partnerships with our security and procurement teams, we have put in place

policies and processes to drive compliance, accountability and awareness of privacy matters at all levels of the organization, enable third-party vendor assessments, and support response to customer and consumer inquiries related to data privacy.

Supply chain and business continuity

Like most companies, we faced pandemic-related supply chain issues in 2021, and our team had to be ready to solve new problems nearly every day — a challenge in the highly regulated healthcare industry. At one time or another, we encountered raw material or labor shortages at Ortho and with our supply chain partners.

“The dedication of our employees to help us meet our delivery deadlines was inspiring. We simply couldn’t have done it without them. It demonstrates the strength of the Ortho culture.”

— Martha McPherson, Head of North America Warehouse Operations, Ortho

Our global distribution center in Memphis, Tennessee, was heavily impacted by COVID-19. We decided to change management and took back control of the distribution of our products, a substantial undertaking. Even running the distribution center ourselves, raw materials and packaging shortages continued, though we managed to solve 85 to 90% of these issues, limiting customer impact.

When we were short-handed and running our distribution center with only 90 people (instead of 130), Ortho employees from a wide variety of roles volunteered to step in to keep the center going.





Product Safety and Quality

Product safety and quality are critical to our business success and to providing patients with potentially lifesaving diagnoses. When we develop tests, they must be extremely sensitive and specific to a disease, so they detect even low levels of incidence. Operations must be able to reproduce the test and meet these standards rapidly and reliably hundreds of millions of times. If the test requires a special container or must be stored in a certain position or at a certain temperature, the supply chain must ensure these conditions can be maintained every time.

2021 audits and certifications

- We hosted 30 external audits with an average of 0.6 observations per inspection (e.g., audits from regulators, notified bodies and customers).
- We hosted ISO 13485:2016 recertification and surveillance inspections with zero (0) deficiencies in three out of four manufacturing sites.
- We completed all of our in vitro diagnostic device regulation quality management system, or IVDR QMS, audits with our two Notified Bodies (TUV and GMED) with favorable outcomes.

Before the COVID-19 pandemic, audits were time-intensive and often involved travel. Due to restrictions in 2020 and 2021, we developed an effective virtual audit process that saves time and money. We plan to continue the virtual process or use a hybrid approach going forward.

Quality assurance

Quality is a cornerstone of how we operate. All Ortho employees are responsible for quality in everything that we do. We provide quality policy training during onboarding for all roles, and we review it annually.

The informal threshold for every Ortho test is whether we would take it ourselves — or give it to a loved one — and trust the results.

In 2021, we created a new, three-member, enterprise-driven Process Excellence team with the mandate to improve operations. Its mission is to inspire, support and encourage a culture of excellence at Ortho through the creation of a standardized set of tools, processes and training. The team identifies opportunities to reduce inefficiencies and waste. By tackling one issue at a time and spending three to four days to create a solution, the team can solve problems quickly and efficiently.

Customer service

Our customer relationships often span decades because we provide continuous support. We anticipate and solve our customers' issues, for example, by making our analyzers quieter to improve our customers' work environment or innovating safer service protocols during the pandemic.

We have a 99% customer retention rate and a 99% customer satisfaction rate, according to global transactional customer surveys.

Ortho was awarded the 2021 IMV ServiceTrak Award for customer service.

- Ranked No. 1 for service for the sixth year in a row
- Ranked first in 35 of the 37 categories
- Our Net Promoter Score (NPS) is 22 points higher than our nearest competitor

Ortho was awarded the 2021 IMV ServiceTrak Award for customer service.

- Ranked No. 1 for service for the sixth year in a row
- Ranked first in 35 of the 37 categories
- Our Net Promoter Score (NPS) is 22 points higher than our nearest competitor

Next Steps

INNOVATION:

- Grow the automated segment of our business
- Expand our capabilities for at-home testing by leveraging the Combinations with Quidel

CORPORATE GOVERNANCE:

- Support increased company and board leadership diversity
- Set formal ESG targets
- Continue to engage our leaders and increase the dialogue around cybersecurity from the top down; continue to have cybersecurity and privacy considerations included at the start of every effort, instead of as an add-on
- Continue to seek improvements in supply chain continuity, reworking our processes to be more flexible and robust

PRODUCT SAFETY AND QUALITY:

- Keep working to eliminate hazardous substances and carcinogens in legacy products or byproducts of manufacturing as we maintain high-quality products and service
- Continue to look for efficiency improvements across our organization



GRI/SASB Indices



ESG Disclosures

ESG DISCLOSURES

On May 27, 2022, Ortho Clinical Diagnostics (“Ortho”) and Quidel Corporation (“Quidel”) completed a business combination (the “Combinations”). As of result of the Combinations, Ortho became a wholly owned subsidiary of QuidelOrtho Corporation. The information below represents Ortho before the Combinations during fiscal year 2021 unless noted otherwise and is subject to change following the Combinations.

Ortho considered the GRI (Global Reporting Initiative) 2016 Sustainability Reporting Standards in the development of this report. This index includes links to information about relevant Disclosures.

GRI Index

General Disclosures

The “General Disclosures” information below represents Ortho during fiscal year 2021 unless noted otherwise and is subject to change following the Combinations.

GRI 102-1*	Name of the organization
	Ortho Clinical Diagnostics Holdings Limited (“Ortho”), a wholly owned subsidiary of QuidelOrtho Corporation (“QuidelOrtho”) as of May 27, 2022.
GRI 102-2*	Activities, brands, products, and services
	2021 10-K, page 5 (“Business”)
GRI 102-3*	Location of headquarters
	In 2021, Ortho’s headquarters were located at 1001 Route 202, Raritan, N.J. 08869. Following the Combinations (as defined below), QuidelOrtho’s headquarters are located at 9975 Summers Ridge Road, San Diego, CA 92121.
GRI 102-4*	Location of operations
	2021 10-K, page 59 (“Properties”)

GRI 102-5*	Ownership and legal form
	Ortho is a private company incorporated under the laws of England and Wales. On May 27, 2022, Ortho consummated a business combination (the “Combinations”) pursuant to a Business Combination Agreement (the “BCA”) entered into as of December 22, 2021, by and among Quidel Corporation, QuidelOrtho, and the other parties thereto. As a result of the Combinations, Ortho and Quidel each became a wholly owned subsidiary of QuidelOrtho, a Delaware corporation that trades on the Nasdaq under the ticker symbol “QDEL.”

GRI 102-6*	Markets served
	Ortho offers in vitro diagnostics products and services to customers across more than 130 countries and territories. For more information, see 2021 10-K, page 5 (“Business”) and page 134 (“Notes to Consolidated Financial Statements - Segments and Geographic Information”).

GRI 102-7*	Scale of the organization
	As of January 2, 2022, Ortho had approximately 4,800 employees and served customers across more than 130 countries and territories. Our net revenues were \$2,042.8 million as of January 2, 2022. For more information, see 2021 10-K, page 17 (“Human Capital Resources”) and page 93 (“Consolidated Statements of Operations”).

GRI 102-8*	Information on employees and other workers																				
	Total number of Ortho employees in 2021 by employment contract (permanent and temporary) by gender:																				
	<table border="1"> <thead> <tr> <th></th> <th>Male</th> <th>Female</th> <th>Not Declared</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>Regular</td> <td>2867</td> <td>1871</td> <td>37</td> <td>4775</td> </tr> <tr> <td>Fix Term</td> <td>23</td> <td>37</td> <td>7</td> <td>67</td> </tr> <tr> <td>Total</td> <td>2890</td> <td>1908</td> <td>44</td> <td>4842</td> </tr> </tbody> </table>		Male	Female	Not Declared	Total	Regular	2867	1871	37	4775	Fix Term	23	37	7	67	Total	2890	1908	44	4842
	Male	Female	Not Declared	Total																	
Regular	2867	1871	37	4775																	
Fix Term	23	37	7	67																	
Total	2890	1908	44	4842																	

	Total number of Ortho employees in 2021 by employment contract (permanent and temporary) by region:																																
	<table border="1"> <thead> <tr> <th></th> <th>ASPAC</th> <th>Greater China</th> <th>EMEA</th> <th>Japan</th> <th>LATAM</th> <th>NA</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>Regular</td> <td>317</td> <td>402</td> <td>1103</td> <td>212</td> <td>339</td> <td>2402</td> <td>4775</td> </tr> <tr> <td>Fix Term</td> <td>3</td> <td></td> <td>35</td> <td>24</td> <td>5</td> <td>0</td> <td>67</td> </tr> <tr> <td>Total</td> <td>320</td> <td>402</td> <td>1138</td> <td>236</td> <td>344</td> <td>2402</td> <td>4842</td> </tr> </tbody> </table>		ASPAC	Greater China	EMEA	Japan	LATAM	NA	Total	Regular	317	402	1103	212	339	2402	4775	Fix Term	3		35	24	5	0	67	Total	320	402	1138	236	344	2402	4842
	ASPAC	Greater China	EMEA	Japan	LATAM	NA	Total																										
Regular	317	402	1103	212	339	2402	4775																										
Fix Term	3		35	24	5	0	67																										
Total	320	402	1138	236	344	2402	4842																										

Total number of Ortho employees in 2021 by employment type (full time and part time) by gender:

	Male	Female	Not Declared	Total
Full Time	2885	1840	43	4768
Part Time	5	68	1	74
Total	2890	1908	44	4842

Ortho hires temporary contractors in various parts of the business, but in 2021 they comprised less than 10% of the global workforce. We do not experience significant variations in these figures. This data was compiled from monthly headcount reporting and excludes contractors and interns due to their small numbers. All data is as of January 2, 2022.

GRI 102-9*	Supply chain
	Our supply chain consists of over 4,000 suppliers across the globe providing electronic equipment, consumables, IT products and services, professional services, indirect materials, professional services, manufacturing supplies, biologics, packaging and logistics. We have approximately 660 diverse and veteran-owned suppliers. For more information, see 2021 10-K, page 15 (“Suppliers and Raw Materials”).
GRI 102-10*	Significant changes to the organization and its supply chain

Ortho completed its Initial Public Offering in February 2021, with its ordinary shares traded on The Nasdaq Global Select Market under the symbol “OCDX”. In addition, on December 22, 2021, Ortho entered into the BCA and the Combinations closed on May 27, 2022, resulting in Ortho becoming a wholly owned subsidiary of QuidelOrtho.

GRI 102-11* Precautionary Principle or approach

Ortho's Safety, Risk Management and Surveillance unit of its Quality, Regulatory and Compliance (QRC) department ensures that product complaints are reviewed, evaluated, documented and investigated when necessary by:

- Evaluating potential health and safety complaints
- Communicating reportable events (i.e., adverse events and Field Safety Corrective Actions ("FSCA")) to applicable regulatory authorities and to relevant Worldwide Ortho Regulatory Affairs groups and local regional representatives
- Interfacing with regulatory authorities for FSCAs
- Analyzing complaint trends and using advanced data analytics to drive product insights
- Escalating significant quality events from nonconformances, complaint trends and potential health and safety events for additional investigation and determination/initiation of Corrective and Preventative Action ("CAPA")
- Authoring health hazard evaluations
- Creating current issue documents

GRI 102-12* External initiatives

- Environmental Health and Safety management system standards to which Ortho voluntarily subscribes to on a nonbinding basis include ISO 14001 and ISO45001 for over 15 years, OSHAS18001 for over 15 years, OSHA VPP for 20 years and ISO45001:2018 as of 2021.
- Quality management systems and regulations to which Ortho subscribes include: EN ISO 13485:2016, MDSAP, USFDA Registration, IVED Directive 98/79/EC, SOR/98-282, MHLW Ordinance no 169, 2014, R.O.C. DOH Designation Medical Device GMP, Directive RDC 16/2103, 23./2012 and 67/2009, Korean Medical Device Regulation, Therapeutic Goods (Medical Devices) Regulations, 2002, Schedule 3 Part 1, Good Manufacturing Practice for Medical Devices.
- Ortho also complies with the Organisation for Economic Co-operation and Development ("OECD") Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas, as well as the applicable requirements of Section 1502 of the Dodd-Frank Act.

GRI 102-13* Membership of associations

Ortho is a member of the Women's Business Enterprise National Council and the National Minority Supplier Development Council.

Strategy

GRI 102-14* Statement from senior decision-maker

Sustainability Report, page 5 ("A message from our Chief Financial Officer")

GRI 102-15 Key impacts, risks, and opportunities

2021 10-K, page 24 ("Risk Factors").

Ethics and integrity

GRI 102-16* Values, principles, standards, and norms of behavior

Code of Business Conduct and Ethics⁹

Corporate Governance Guidelines¹⁰

GRI 102-17 Mechanisms for advice and concerns about ethics

Whistleblower Policy¹¹

QuidelOrtho maintains an Ethics Hotline, which is available 24 hours a day, 7 days a week, as described in its Code of Business Conduct and Ethics.

Governance

The "Governance" information below represents Ortho during fiscal year 2021 unless noted otherwise and is subject to change following the Combinations.

GRI 102-18* Governance structure

Ortho values robust corporate governance practices as a means to protect our business, reputation, investor confidence, and our relationships with our customers, suppliers, and employees. For more information, see 2022 Proxy Statement, page 14 ("Board of Directors and Corporate Governance").

GRI 102-19 Delegating authority

Ortho's Board of Directors (the "Board") delegated to the Nominating and Governance Committee authority over corporate governance matters and approval of environmental, social and governance ("ESG") reporting. In 2021, senior management periodically updated the Board on ESG matters and was responsible for implementing Ortho's 2021 ESG plan.

GRI 102-20 Executive-level responsibility for economic, environmental, and social topics

In 2021, in connection with Ortho's 2021 ESG plan, Ortho's Head of Quality, Regulatory, Compliance, Clinical, Medical and Scientific Affairs was responsible for environmental issues, Ortho's Head of People & Culture was responsible for social issues, and Ortho's Executive Vice President, General Counsel and Secretary was responsible for governance issues.

GRI 102-21 Consulting stakeholders on economic, environmental, and social topics

In connection with its 2022 Sustainability Report, Ortho consulted with internal and external stakeholders on economic, environment, and social topics as part of our materiality assessment. We also consulted stakeholders on the Combination with Quidel in early 2022 with the help of communications advisors.

GRI 102-22 Composition of the highest governance body and its committees

In 2021, Ortho's Board was composed of 90% nonexecutive directors and 80% of our directors were independent based on the Nasdaq Listing Rules. In 2021, Ortho's Articles of Association required a classified result. As a result, our Board consisted of 2 Class I directors, 4 Class II directors, and 4 Class III directors and 20% of our directors identified as female. One director, David Perez, serves as a director of the Executive Partnership to Invest in Children (EPIC), a Colorado nonprofit that supports working families and children's education, and Fitzsimons Innovation Community, a business park and community focused on healthcare innovation. Another director, Allen Holt, serves as Chairman of the Board of the Smithsonian National Air and Space Museum, Vice Chairman of the council of the United States Holocaust Memorial Museum, a member of the Johns Hopkins University Wilmer Eye Institute Board of Governors, and a member of the George W. Bush Presidential Center's Human Freedom Advisory Council.

For more information, see 2022 Proxy Statement, page 14 ("Board of Directors and Governance").

⁹As a result of the Combinations effective May 27, 2022, QuidelOrtho Corporation's Code of Business Conduct replaced Ortho's policy.

¹⁰As a result of the Combinations effective May 27, 2022, QuidelOrtho Corporation's Corporate Governance Guidelines replaced Ortho's corporate guidelines.

¹¹As a result of the Combinations effective May 27, 2022, QuidelOrtho Corporation's Whistleblower Policy replaced Ortho's policy.

GRI 102-23 Chair of the highest governance body

In 2021, Christopher Smith served as Ortho's Chairman of the Board and our Chief Executive Officer. For more information on Mr. Smith's function within the organization's management and the reasons for this arrangement, see 2022 Proxy Statement, page 20 ("Leadership Structure of the Board").

GRI 102-24 Nominating and selecting the highest governance body**Director qualification standards and additional selection criteria:**

Prior to the Combinations, Ortho's Articles of Association required the Board to be divided into three classes of directors, with the directors serving staggered three-year terms, with only one class of directors being elected at each annual meeting of shareholders. In 2021, Ortho's Nominating and Corporate Governance Committee was responsible for recommending director candidates for election to the Board who have a high level of personal and professional integrity, strong ethics and values and the ability to make mature business judgments.

Ortho's Nominating and Corporate Governance Committee and the Board were also committed to actively seeking out highly qualified women and individuals from minority groups to include in the pool from which new Board candidates are chosen. For more information, see 2022 Proxy Statement, page 22 ("Nominating and Corporate Governance Committee").

GRI 102-25 Conflicts of interest

Code of Business Conduct and Ethics, page 3

2022 Proxy Statement, page 12 ("Transactions with Related Person")

GRI 102-26 Role of highest governance body in setting purpose, values, and strategy

In 2021, Ortho's Global Leadership Team (GLT) and Board were responsible for establishing our purpose, values and strategy. For more information, see 2022 Proxy Statement, page 24 ("Board Oversight of Risk Management").

GRI 102-27 Collective knowledge of highest governance body

In 2021, Ortho's Board was comprised of experts and leaders in their respective fields. For example, seven of Ortho's directors served as a chief executive officer, seven had careers in industries relevant to our business, and three are experts in finance and investment matters. Further, in 2021 Ortho's Audit Committee was comprised entirely of directors designated as "financial experts" pursuant to the U.S. securities laws and Nasdaq listing requirements. In 2021, Ortho regularly provided financial information through our quarterly and year-end earnings releases and calls. For more information, please refer to our press releases available on QuidelOrtho's website and see 2022 Proxy Statement, page 14 ("Board of Directors and Corporate Governance").

GRI 102-28 Evaluating the highest governance body's performance

In 2021, Ortho's Nominating and Corporate Governance Committee was responsible for overseeing the periodic self-evaluations of the Board. For more information, see 2022 Proxy Statement, page 22 ("Nominating and Corporate Governance Committee").

GRI 102-30 Effectiveness of risk management processes

In 2021, Ortho had an enterprise risk management process, led by its internal audit function, whereby significant risks, including economic, environmental, and social issues were identified and taken into consideration in connection with internal audit planning and actions. Pursuant to Ortho's Audit Committee Charter, Ortho's Audit Committee was charged with discussing and reviewing Ortho's policies with respect to risk assessment and risk management. Accordingly, in 2021 Ortho's Audit Committee was regularly apprised of the enterprise risk management plan, issues, and higher-risk audit findings. For more information, see 2022 Proxy Statement, page 24 ("Board Oversight of Risk Management").

GRI 102-32 Highest governance body's role in sustainability reporting

Pursuant to the Nominating and Corporate Governance Committee Charter, the Board delegated to the Nominating and Corporate Governance Committee authority to approve Environmental, Social and Governance Reporting. Additionally, certain senior executives of our Global Leadership Team reviewed and provided input to our 2022 Sustainability Report prior to publication.

GRI 102-33 Communicating critical concerns

Ortho's Code of Business Conduct and Ethics set forth procedures for our directors, employees and temporary workers to communicate critical concerns to Ortho, including reporting such concerns to Ortho's Ethics Hotline. The Audit Committee was updated on a regular basis of any material reports of known or suspected violations of the law or the Code. In addition, Ortho's Policy Regarding Shareholder Communications with the Board set forth how our shareholders could communicate directly with the independent members of the Board or the Chairman about corporate governance, corporate strategy, Board-related matters or other substantive matters. For more information, see 2022 Proxy Statement, page 25 ("Communications with Directors").

GRI 102-35 Remuneration policies

In 2021, the main elements of Ortho's executive compensation program included 1. base salary, 2. cash-based incentive compensation, 3. equity-based incentive compensation, and 4. limited executive perquisites. For more information, see 2022 Proxy Statement, page 29 ("Executive Compensation Discussion and Analysis").

In 2021, the main elements of Ortho's nonexecutive director compensation program included 1. an annual cash retainer, 2. annual equity award, and 3. annual chair fees for the Chairs of our Audit, Compensation, and Nomination and Corporate Governance Committees. For more information, see 2022 Proxy Statement, page 26 ("Nonexecutive Director Compensation").

Finally, in 2021, Ortho's Insider Trading & Compliance Policy¹² prohibited all officers, directors, and employees from speculating in Ortho's shares, including short selling, derivative transactions, hedging transactions, margin purchases and pledging activities, subject to certain limited exceptions.

GRI 102-36 Process for determining remuneration

In 2021, Ortho's Compensation Committee was responsible for developing and administering our executive compensation program. The Compensation Committee worked closely with its independent consultant and met regularly to make decisions on our executive compensation program and to discuss the compensation of our senior executive officers and nonexecutive directors. In performing its duties, the Compensation Committee met periodically with the CEO to review compensation policies and specific levels of compensation paid to our senior executives (other than the CEO) and certain other key personnel. For more information, see 2022 Proxy Statement, page 29 ("Executive Compensation Discussion and Analysis").

¹²As a result of the consummation of the Combinations effective May 27, 2022, QuidelOrtho Corporation's Insider Trading & Compliance Policy replaced Ortho's policy.

GRI 102-38 Annual total compensation ratio

In 2021, the estimated ratio of the annual total compensation of our CEO to the median of the annual total compensation of all other employees was approximately 68:1. For more information, see 2022 Proxy Statement, page 43 (“CEO Pay Ratio”).

Stakeholder engagement*

GRI 102-40* List of stakeholder groups

Sustainability Report, page 8 (“Materiality Assessment”)
2021 UK Annual Report, page 50 (“Section 172(1) UK Companies Act 2006”)

GRI 102-41* Collective bargaining agreements

Percentage of total employees covered by collective bargaining agreements.
2021 10-K, page 17 (“Human Capital Resources”)

GRI 102-42* Identifying and selecting stakeholders

The basis for identifying and selecting stakeholders with whom to engage.
Sustainability Report, page 8 (“Materiality Assessment”)

GRI 102-43* Approach to stakeholder engagement

Our primary stakeholders include our employees, suppliers, customers, and investors. For more information, see Sustainability Report, page 8 (“Materiality Assessment”).
2021 UK Annual Report, page 50 (“Section 172(1) UK Companies Act 2006”)

GRI 102-44* Key topics and concerns raised

2021 UK Annual Report, page 50 (“Section 172(1) UK Companies Act 2006”)

Reporting practice*

GRI 102-45* Entities included in the consolidated financial statements

In 2021, Ortho had five geographically based operating segments: Americas, Europe the Middle East and Africa (“EMEA”), Greater China, Japan and Asia Pacific (“ASPAC”). For more information, see 2021 10-K, page (“Consolidated Financial Information”).

GRI 102-46* Defining report content and topic boundaries

Sustainability Report, page 8 (“Materiality Assessment”)

GRI 102-47* List of material topics

Sustainability Report, page 8 (“Materiality Assessment”)

GRI 102-48* Restatements of information

Not applicable. This is our first report.

GRI 102-49* Changes in reporting

Not applicable. This is our first report.

GRI 102-50* Reporting period

This report is for the 2021 fiscal year ended January 2, 2022.

GRI 102-51* Date of most recent report

This is Ortho's first sustainability report.

GRI 102-52* Reporting cycle

We plan to report annually.

GRI 102-53* Contact point for questions regarding the report

Bryan Brokmeier, CFA, Vice President, Investor Relations, QuidelOrtho Corporation (IR@quidel.com).

GRI 102-54* Claims of reporting in accordance with the GRI Standards

This report has been prepared in accordance with the GRI Standards: Core option.

GRI 102-55* GRI content index

Sustainability Report, page 37.

GRI 102-56* External assurance

Currently, we do not have any policies or current practice with regard to seeking external assurance for this sustainability report.

Economic

Economic performance

GRI 201 Management approach

2021 10-K, page 5 (“Business”)

GRI 201-1 Direct economic value generated and distributed

We sell our products and services in more than 130 countries worldwide and have a direct presence in 36 countries. We support these commercial operations with approximately 2,300 commercial sales, service and regional marketing teammates and a network of more than 300 distributors globally. We also have an extensive global network of manufacturing and distribution centers that allows us to be closer and more responsive to our customers while managing and optimizing our cost structure. Our global footprint allows us to effectively launch our new product innovations, including instrument platform developments and new assays, across the globe. Our geographic balance also provides revenue diversification, which helps us to hedge against currency fluctuations and potential regional economic downturns.

Ortho's net revenues were \$2,042.8 million as of January 2, 2022. For more information, see 2021 10-K, page 90 (“Consolidated Financial Statements”).

GRI 201-3 Defined benefit plan obligations and other retirement plans

2021 10-K, page 121 (“Note 14 - Long-Term Employee Benefits”)

GRI 201-4 Financial assistance received from government

2021 10-K, page 22 (“U.S. healthcare laws”)

2021 10-K, page 93 (“Consolidated Statements of Operations”)

2021 10-K, page 106 (“Note 3(x) - Summary of Significant Accounting Policies, Government Grants”)

Procurement practices

GRI 204 Management approach

Ortho is committed to partnering with and expanding opportunities to diverse suppliers by incorporating them into the everyday process of category reviews and product or service bids. Six categories of suppliers that Ortho engages in business with are:

- Small Businesses (SB)
- Small Disadvantaged Businesses (SDB)
- Women-Owned Small Businesses (WOSB)
- Veteran-Owned Small Businesses (VOSB)
- Service-Disabled Veteran-Owned Small Businesses (SDVOSB)
- HUBZone Small Businesses (HUBZone)

By identifying and promoting diverse suppliers, Ortho is able to deliver world-class products and services that enable healthcare providers to better treat their patients. Additionally, Ortho is an active member in the Women's Business Enterprise National Council and National Minority Supplier Development Council.

Anti-corruption

GRI 205 Management approach

We are committed to high standards of integrity and ethical business conduct. Ortho's Code of Business Conduct and Ethics prohibited the company's employees, directors and agents from giving or receiving bribes, kickbacks or other inducements in order to obtain an improper business advantage. For information, see Code of Business Conduct and Ethics and Compliance Program.

GRI 205-3 Confirmed incidents of corruption and actions taken

Ortho does not publicly discuss issues relating to anti-bribery and anti-corruption.

Anti-competitive behavior

GRI 206 Management approach

For information about our management approach regarding competition and fair dealing, see our Code of Business Conduct and Ethics.

GRI 206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices

None.

Tax

GRI 207 Management approach

Ortho is a leading global provider of in vitro solutions for screening, diagnosing and monitoring diseases. Our products are sold in more than 130 countries, and we have a direct commercial presence in more than 30 countries. Our business activities around the world incur a substantial amount and variety of business taxes. Taxes incurred by Ortho includes corporate income taxes, customs duties, excise taxes, employment and many other business taxes in all jurisdictions where applicable. In addition, Ortho collects and pays employee taxes and indirect taxes such as Value Added Taxes.

For additional information, see Ortho's 2021 Tax Strategy Statement (https://www.orthoclinicaldiagnostics.com/assets/pdf/EMEA/uk_tax_strategy_2020.pdf) that details our approach to the tax governance of Ortho and is published in accordance with the requirements of Paragraph 16(2), Schedule 19 of the Finance Act 2016 for the financial year ended January 3, 2021.

GRI 207-1 Approach to tax

GRI 207-2 Tax governance, control, and risk management

GRI 207-3 Stakeholder engagement and management of concerns related to tax

Ortho's 2021 Tax Strategy Statement — <https://www.orthoclinicaldiagnostics.com/assets/pdf/EMEA/uk-tax-strategy-2021.pdf>

Environmental

The "Environmental" information below represents Ortho during fiscal year 2021 unless noted otherwise and is subject to change following the Combinations.

Materials

GRI 301 Management approach

For information about our management approach regarding environmental matters, see Sustainability Report, page 11 ("Environment: Reducing the environmental impact of our operations and products").

GRI 301-2 Recycled input materials used

Due to the medical nature of Ortho's products, there is no recycled content used in the actual products themselves. The vast majority of the packaging associated with our analyzers is corrugated, which typically contains 70% recycled content. Ortho reagents are packaged with cardstock which may contain recycled content in varying amounts depending on the product line and manufacturing facility.

GRI 301-3 Reclaimed products and their packaging materials

Ortho's consumables, which includes reagents, calibrators and controls, cannot be reclaimed to be recycled. Our diagnostic analyzers comprised of metals and plastics can theoretically be recycled. Given the practical limitation in separating some of the assemblies, Ortho estimates 65% of analyzer components are recyclable. Ortho maintains a program to take back and refurbish or recycle analyzers.

Energy

GRI 302 Management approach

For information about our management approach regarding energy matters, see Sustainability Report, page 12 (“GHG Emissions and Energy Use”).

GRI 302-1 Energy consumption within the organization

Energy Consumption	MWh	Scope
Total fuel consumption from nonrenewable sources	212,548	
Total fuel consumption from renewable sources	16,113	
Total electricity consumption	64,533	Grid + solar
Heating consumption	41,700	ROC purchased steam and Geo
Cooling consumption	31,866	ROC purchased cooling water
Steam consumption	58,894	Natural Gas Use
Total energy consumption	228,661	

The source of the conversion factors used in the above calculations can be found in EPA’s Simplified GHG Calculator which is aligned with the Greenhouse Gas Protocol.

GRI 302-3 Energy intensity

The energy intensity ratio for Ortho can be found on p. 12 of our Sustainability Report. The ratio is the kWh of all energy sources (inside and outside of Ortho) divided by total company revenue.

GRI 302-4 Reduction of energy consumption

Our reductions in energy consumption can be found on pages 12 and 13 of our Sustainability Report. Reduction in energy consumption is defined as the percent change in total energy consumption (in kWh) for all energy sources (inside and outside Ortho) between the base year and the current year. Energy consumption figures for these years are derived from utility meter billing statements.

Water

GRI 303 Management approach

For information about our management approach regarding water matters, see our Sustainability Report, page 12 (“GHG Emissions and Energy Use”) and page 20 (“Next-Generation Goals”).

GRI 303-1 Interactions with water as a shared resource

Water withdrawn to support Ortho’s operations is sourced from each facilities’ local or regional water authority. Ortho does not engage in sourcing water independently from onsite sources as lakes, rivers and aquifers. All sites discharge used water to a local or regional sewer authority with pretreatment and final treatment. Ortho’s major water consumption occurs in New Jersey, Florida, New York, and Pencoed, Wales, which are not classified as water stressed regions. Our 2021 goal was to maintain our 2018 levels of water consumption.

GRI 303-2 Management of water discharge-related impacts

Ortho’s wastewater discharges are subject to the discharge standards established by the governing sewer authority. In some circumstances, Ortho operates under the conditions of a wastewater permit obtained from the local authority. Ortho’s major water consumption occurs in New Jersey, Florida, New York, and Pencoed, Wales, which are not classified as water stressed regions.

GRI 303-3 Water withdrawal

Water withdrawn is a measurement of water used at each of Ortho’s major facilities. These facilities receive their water from a third party (i.e., a water company), which may use multiple water sources including surface water and aquifer. The 2021 Ortho water withdrawal as described is 105 million gallons. Ortho’s major water consumption occurs in New Jersey, Florida, New York and Pencoed, Wales, which are not classified as water stressed regions.

GRI 303-4 Water discharge

None of Ortho’s major facilities have direct water discharges to the environment. All facilities discharge wastewater to a publicly owned and operated wastewater treatment plant. Ortho’s major water consumption occurs in New Jersey, Florida, New York and Pencoed, Wales, which are not classified as water stressed regions.

GRI 303-5 Water consumption

Sustainability Report, page 19 (“Waterless Technology and Water Use”).

Emissions

GRI 305 Management approach

For information about our management approach for this topic, see Sustainability Report, page 12 (“GHG Emissions and Energy Use”).

GRI 305-1 Direct (Scope 1) GHG emissions

For our Scope 1 emissions data, see Sustainability Report, page 12 (“GHG Emissions and Energy Use”). Our biogenic emissions are not included in these calculations because they are negligible. The baseline year for our emissions calculations is 2019, as this was the year with the most complete energy dataset to apply carbon equivalent conversion factors.

GRI 305-2 Energy indirect (Scope 2) GHG emissions

For our Scope 2 emissions data, see Sustainability Report, page 12 (“GHG Emissions and Energy Use”). The GHG tool used to calculate CO2 equivalents takes into consideration all GHGs; however, Ortho’s data set is not conclusive for refrigerants. The baseline year for our emissions calculations is 2019, as this was the year with the most complete energy dataset to apply carbon equivalent conversion factors.

GRI 305-3 Other indirect (Scope 3) GHG emissions

Ortho has limited sources of scope 3 emission data and as a result, this Sustainability Report does not include such Scope 3 data.

GRI 305-4 GHG emissions intensity

For our GHG emissions intensity figures, see: Sustainability Report, page 12 (“GHG Emissions and Energy Use”).

GRI 305-5 Reduction of GHG emissions

For our GHG emissions reduction figures, see Sustainability Report, page 12 (“GHG Emissions and Energy Use”). The GHG tool used to calculate CO2 equivalents takes into consideration all GHGs; however, Ortho’s data set is not conclusive for refrigerants. The baseline year for our emissions calculations is 2019, as this was the year with the most complete energy dataset to apply carbon equivalent conversion factors.

GRI 305-6 Emissions of Ozone-Depleting Substances (ODS)

Each Ortho facility maintains Ozone-Depleting Substances (“ODS”) emission records. Ortho does not have a consolidated report at this time.

GRI 305-7 Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions

Each major Ortho facility maintains a NOX and SOX potential to emit. Ortho does not have consolidated NOX and SOX emissions figures at this time.

Waste

GRI 306 Management approach

For information about our management approach for waste matters, see Sustainability Report, page 14 (“Waste and Hazardous Materials”) and page 19 (“Waterless Technology and Water Use”).

GRI 306-2 Management of significant waste-related impacts

Supplier agreements are in place with all waste haulers used to support our major facilities. The agreements require all haulers to operate in compliance with all laws regulations and Ortho reserves the right to audit and visit these facilities.

GRI 306-3 Waste generated

For information on our waste generation, see Sustainability Report, page 14 (“Waste and Hazardous Materials”).

GRI 306-4 Waste diverted from disposal

For information on our waste diversion, see Sustainability Report, page 14 (“Waste and Hazardous Materials”).

GRI 306-5 Waste directed to disposal

For information on our waste directed to disposal, see Sustainability Report, page 14 (“Waste and Hazardous Material”).

Social

The “Social” information below represents Ortho during fiscal year 2021 unless noted otherwise and is subject to change following the Combinations.

Employment

GRI 401 Management approach

For information about our management approach for employment matters, see Sustainability Report, page 26 (“Employee Recruitment, Engagement and Development”).

GRI 401-1 New employee hires and employee turnover

New employee hires 2021

20 and under	21-30	31-40	41-50	51-60	61-64	65 and over	Blank	Total
13	316	295	162	118	23	6	29	962

Male	Female	Not Declared	Total
528	394	40	962

ASPAC	Greater China	EMEA	Japan	LATAM	NA	Total
46	99	184	25	57	551	962

The above figures include all regular and fixed-term employee hires between January 3, 2021, and January 2, 2022, regardless of whether they are currently employed by Ortho or not. Ages are listed as of time of hire. These figures do not include contractors or interns.

Employee turnover 2021

ASPAC	Greater China	EMEA	Japan	LATAM	NA	Total
7.8%	16.1%	8.2%	8.7%	9.4%	16.8%	13.3%

The above figures include regular employees only, not fixed-term contract employees or interns. These figures are for calendar year 2021 due to the negligible difference between the calendar year and our fiscal year (January 3 – January 2).

GRI 401-3 Parental leave

All U.S. employees are entitled to parental leave after the birth or adoption of a child. Outside the U.S., Ortho follows local statutory requirements. The following table shows parental leave data for U.S. employees, not including Family Medical Leave Act (“FMLA”) leave:

	Female	Male	Grand Total
Active (returned to work in the reporting period after leave)	20	22	42
Term (did not return)	6	2	8
Grand Total	26	24	50

Occupational health and safety

GRI 403 Management approach

For information about our management approach for occupational health and safety matters, see Sustainability Report, page 20 (“Environmental Health and Safety Standards”).

GRI 403-1 Occupational health and safety management system

For information about our occupational health and safety management system, see Sustainability Report, page 20 (“Environmental Health and Safety Standards”).

GRI 403-2 Hazard identification, risk assessment and incident investigation

Ortho manufacturing sites are certified to ISO45001 or OSHA’s Voluntary Protection Program. These are management systems for the control of workplace occupational health and safety hazards. The sites certified to the ISO45001 or OSHA Voluntary Protection Program, as well as those that are not certified, have established Environmental Health & Safety Management Systems (EHMS) that document and govern processes for assessing risk, managing work-related hazards, ensuring worker safety and protection, and managing work-related incidents as well as continuously improving the EHMS itself.

GRI 403-3 Occupational health services

Ortho Manufacturing sites are certified to ISO45001 or OSHA’s Voluntary Protection Program. These are management systems for the control of workplace occupational health and safety hazards. The sites certified to the ISO45001 or OSHA Voluntary Protection Program, as well as those that are not certified, have established Environmental Health & Safety Management Systems (EHMS) that document and govern processes for assessing risk, managing work-related hazards, ensuring worker safety and protection and implementing the hierarchy of controls (elimination, substitution, engineering controls, administrative controls, PPE) to minimize or eliminate risk. Facility risk assessments and internal/external audits are conducted to quantify the risk associated with specific tasks, which aids Ortho in determining the appropriate safety controls to be implemented.

GRI 403-4 Worker participation, consultation and communication on occupational health and safety

Employees and contractors (i.e., contingent workers) who work at an Ortho facility are integrated into the site’s EHS programs and procedures. Employee and contractor incidents at a facility are recorded and investigated in accordance with Ortho’s injury and illness procedures. The employee and contractor injuries are actively tracked, trended, and reported to management representatives. Workers, including supervisors, are included as part of the injury and incident review process to understand the root cause and implement any corrective action(s). Workers are involved in EHS committees, development of job hazard analysis, risk assessments and site inspections. Health and safety metrics are communicated to workers, supervisors, managers and the global leadership team. In 2021, health and safety metrics were communicated through the local safety committees, function/department-specific meetings including with Global Leadership Team monthly and Environmental Health & Safety Management System Review meetings, and on Ortho’s company website.

GRI 403-5 Worker training on occupational health and safety

Ortho provides occupational health and safety training through a learning management system. This includes general occupational health and safety training such as EHS General Awareness, Emergency Procedures, Chemical Safety and Hazard Communication, Ergonomics and Personal Protective Equipment. Additionally, employees and contractors (i.e., contingent workers) receive EHS training required for job-specific tasks. Job-specific training includes machine safety, cold stress, electrical safety, respiratory protection and job hazard analysis (JHAs). This training is performed through a combination of the learning management system, instructor-led training and supervisor training.

GRI 403-6 Promotion of worker health

Ortho has an Occupational Health Department that provides services such as pre-employment screening, medical surveillance, health screenings, nonoccupational visits for minor injuries/illnesses, first-aid care, modified duty, work accommodations, return to work, health profiles and biometrics, business travel consultations, work fitness for duty evaluations, flu clinics, health fairs, an employee assistance program and physical activity fitness programs. The Occupational Health Department is an internal function within Ortho and available to employees and contractors either onsite (specific office locations), virtually or via phone. All individual medical information is strictly confidential.

GRI 403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships

Ortho conducts health and safety risk assessments to identify and proactively mitigate significantly negative occupational health and safety impacts through a hierarchy of safety controls.

GRI 403-8 Workers covered by an occupational health and safety management system

Our Occupational Health & Safety Management system covers 54% (3,491 of 6,511) of employees and workers who are not employees, but whose work and/or workplace is controlled by the organization. These systems have been internally audited as well as externally audited by an accredited third party.

GRI 403-9 Work-related injuries

Minimizing work-related injuries is a priority for us and we are continuously evaluating ways to reduce accidents in the workplace. The table below reflects 2021 U.S. data only.

Total Case Incident Rate (TCIR)*	1.5*
Lost Time Accident (LTA) Rate	0.5*
Total Number of Reportable Injuries	48
Category	Percentage
Other (i.e., COVID Illness)	21%
Ergonomics – Overexertion	21%
Ergonomics – Repetitive Motion	19%
Exposure	11%
Slip, Trip, Fall	10%
Struck By or Against	6%
Contact With	6%
Motor Vehicle Accident	4%

*Ortho’s rates are below the 2021 industry average according to the U.S. Bureau of Labor and Statistics.

GRI 403-10 Work-related ill health

See GRI 403-9.

Training and education

GRI 404 Management approach

For information about our management approach for training and education matters, see Sustainability Report, page 26 (“Employee Recruitment, Engagement and Development”).

Diversity and equal opportunity

GRI 405 Management approach

For information on our management approach for diversity and equal opportunity matters, see Sustainability Report, page 24 (“Diversity, Equity & Inclusion”).

GRI 405-1 Diversity of governance bodies and employees

See Sustainability Report, page 24 (“Diversity, Equity & Inclusion”).

Nondiscrimination

GRI 406 Management approach

For information about our management approach for nondiscrimination matters, see Sustainability Report, page 24 (“Diversity, Equity & Inclusion”) and our Code of Business Conduct and Ethics.

GRI 406-1 Incidents of discrimination and corrective actions taken

None

Customer health and safety

GRI 416 Management approach

In 2021, Ortho invested \$1M in product quality improvement programs. In general, approximately 40% of Ortho’s R&D spend annually is allocated to support existing products, so we are continually investing in our product lifecycle management.

GRI 416-1 Assessment of the health and safety impacts of product and service categories

Ortho’s products are documented in accordance with the Globally Harmonized System of Classification and Labeling of Chemicals (GHS), with Safety Data Sheets (SDS) available that document each product’s physical and chemical properties, exposure hazards, safe handling and transport, cleanup instructions and first aid, toxicology, pollution risks and disposal considerations. For those products that require Safety Data Sheets, they are available in the country-of-origin languages and can be downloaded from a portal on the Ortho website. In addition, our instruments are designed and manufactured in compliance with regulations such as the Restriction of Hazardous Substances (RoHS) and Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) directives, ensuring that their constituent materials do not pose harm to personnel involved in their assembly, service or decommissioning. Furthermore, Ortho products used in clinical laboratory environments comply with applicable requirements in their countries of sale with regards to In Vitro Diagnostic (IVD) and Research-Use Only (RUO) products.

GRI 416-2 Incidents of noncompliance concerning the health and safety impacts of products and services

During 2021, Ortho did not identify any noncompliance with regulations and/or voluntary codes within the reporting period.

SASB INDEX

The information below represents Ortho during fiscal year 2021 unless noted otherwise and is subject to change following the Combinations.

MEDICAL EQUIPMENT & SUPPLIES

Affordability & Pricing

HC-MS-240a.1. Ratio of weighted average rate of net price increases (for all products) to the annual increase in the U.S. Consumer Price Index

Prices are contracted with each customer. In general, we face an estimated 1%-1.5% price pressure on our business each year.

HC-MS-240a.2. Description of how price information for each product is disclosed to customers or to their agents

Price information for products is disclosed to customers through contracts entered into with every customer.

Product Safety

HC-MS-250a.1 Number of recalls issued, total units recalled

Year	Class I	Class II	Class III
2021	0	9	7
2020	0	9	4
2019	0	12	3
2018	0	7	5

Note: we have provided U.S. only data, as the classifications below are US FDA and a good representation of our recall volumes.

HC-MS-250a.2 List of products listed in the FDA’s MedWatch Safety Alerts for Human Medical Products database

None.

HC-MS-250a.3 Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device Experience

None.

HC-MS-250a.4 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type

None.

Ethical Marketing

HC-MS-270a.1 Total amount of monetary losses as a result of legal proceedings associated with false marketing claims

None.

HC-MS-270a.2 Description of code of ethics governing promotion of off-label use of products

Pursuant to its Code of Business Conduct and Ethics, Ortho is committed to providing quality products and services to its customers in compliance with applicable laws and regulations governing the development, manufacturing, labeling and approving of those products.

Product Design & Lifecycle Management

HC-MS-410a.1 Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products

Sustainability Report, page 11 (“Environment: Reducing the environmental impact of our operations and products”).

HC-MS-410a.2 Total amount of products accepted for takeback and reused, recycled or donated, broken down by: (1) devices and equipment and (2) supplies

Information currently not available.

Supply Chain Management

HC-MS-430a.1 Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product quality

Pursuant to its Code

HC-MS-430a.2 Description of efforts to maintain traceability within the distribution chain

Ortho maintains product traceability throughout the distribution chain via a global Enterprise Resource Management (ERP) system. Ortho ensures mandatory product and customer data fields are populated and maintained to ensure rapid data identification and retrieval concerning all shipments to our customers and distributors around the globe. All Ortho products have a product code (catalog number), and where applicable, a serial number or lot number for traceability throughout the product lifecycle. Certificates of Analysis (for assays) and Certificates of Conformance (for instruments) are available to customers and distributors through Ortho's Technical Support Center or online through our Ortho Plus online portal.

Ortho's Quality Regulatory and Compliance team, along with Supply Chain Management and International Logistics teams coordinate timely market access and delivery to our customers. Ortho products are sold and marketed globally in accordance with international regulatory and customs compliance requirements.

HC-MS-430a.3 Description of the management of risks associated with the use of critical materials

Ortho's approach to product lifecycle management takes account of the risks associated with the use of critical materials to ensure environmental and regulatory compliance requirements are met, as well as continuity of product supply to our customers remains uninterrupted. This includes:

- The assessment of compliance to regulations such as the Restriction of Hazardous Substances ("RoHS") Directive, Registration Evaluation Authorization and Restriction of Chemicals (REACH), Substances of Concern in Products ("SCIP").
- An established Conflict Minerals program in accordance with OECD guidelines to annually survey our suppliers concerning their use of conflict minerals.
- Product labelling that complies with the Globally Harmonized System of Classification and Labelling of Chemicals ("GHS") to ensure our customers can easily recognize any precautions or hazards associated with the use or handling of our products.
- Continuous monitoring and reporting of substance or material production and import volumes as required by the countries where we operate and/or sell our products.

Business Ethics

HC-MS-510a.1 Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption

Ortho does not publicly discuss issues relating to anti-bribery and anti-corruption.

HC-MS-510a.2 Description of code of ethics governing interactions with healthcare professionals

In 2021, Ortho's Healthcare Organizations ("HCOs") and Healthcare Professionals ("HCPs") Interaction Policy was in effect. This policy established global standards and principles to ensure that our interactions with HCPs/HCOs and customers are conducted in an appropriate and legal manner. In sum, the stated policy regarding Ortho's interactions with HCPs, HCOs, or customers is that:

- Ortho will meet the highest standards of ethics, integrity and transparency in all interactions with HCPs/HCOs and customers
- Ortho will comply with all applicable international and local laws and regulations ("Laws") and Ortho's Code of Business Conduct and Ethics

All global employees and representatives of Ortho, including contractors, distributors and third-party intermediaries, are required to comply with this policy.

Table 2. Activity Metrics

HC-MS-000.A Number of units sold by product category

Ortho does not publicly disclose sales volume by number of units sold.

Forward-Looking Statements:

This report of QuidelOrtho Corporation (“QuidelOrtho”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements and other forward-looking statements in this report by words such as “may,” “will,” “would,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “continue,” or similar words, expressions or the negative of such terms or other comparable terminology. These statements include, but are not limited to, the benefits and results of the business combination by and among QuidelOrtho, Quidel Corporation (“Quidel”), Ortho Clinical Diagnostics Holdings plc (“Ortho”) and certain other entities (the “Combinations”) and integration of the businesses of Quidel and Ortho, including QuidelOrtho’s execution of cost and revenue synergies, commercial, integration and other strategic goals, future financial and operating results, future plans or ESG-related goals, objectives, strategies, expectations and intentions and other statements that are not historical facts. Such statements are based on the current beliefs and expectations of QuidelOrtho’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the Combinations; the ability to retain key employees; and other economic, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally. Additional risks and factors are identified under “Risk Factors” in QuidelOrtho’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on August 5, 2022, and subsequent reports filed with the Commission. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. QuidelOrtho has no obligation to update any of the forward-looking information or time-sensitive information included in this report, whether as a result of new information, future events, changed expectations or otherwise, except as required by law. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date hereof. Goals are aspirational and not guarantees or promises that all goals will be met. Statistics and metrics relating to ESG matters are estimates and may be based on assumptions or developing standards.



At QuidelOrtho, we are driven to transform diagnostic data into answers, understanding and action for more people in more places every day. For over 80 years, we’ve relentlessly pursued the unknown with a passion and purpose to improve health. And we’ll continue to transform the power of diagnostics into a healthier future for all.

9975 Summers Ridge Road
San Diego, CA 92121 USA

800-874-1517
[quidelortho.com](https://www.quidelortho.com)

© QuidelOrtho 2022